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ABBREVIATIONS AND SYMBOLS 
1D      one-dimensional 
2D     two-dimensional 
AEA    anandamide 
APCIMS   atmospheric pressure chemical ionization mass spectrometry 
BBB    blood-brain barrier 
CB     cannabinoid 
CNS    central nervous system 
COSY    correlated spectroscopy 
CPC    centrifugal partition chromatography 
DAD    diode array detector 
ESIMS     electronspray ionization mass spectrometry 
ECS    endocannabinoid system 
FAAH    fatty acid amide hydrolase 
HMBC    heteronuclear multiple-bond correlation spectroscopy 
HPLC     high-performance liquid chromatography 
HRE(S)IMS   high-resolution electron(spray) ionization mass spectrometry 
HSQC     heteronuclear single-quantum coherence spectroscopy 
JMOD     J-modulated spin-echo experiment 
MPLC    medium pressure liquid chromatography 
MS     mass spectrometry 
MTCA    1R,3S-1-Methyltetrahydro-β-carboline-3-carboxylic acid 
NAA     N-alkylamides 
NMR     nuclear magnetic resonance 
NOESY    nuclear Overhauser effect spectroscopy 
PLC    preparative thin-layer chromatography 
RBEC    rat brain endothelial cell 
RP     reversed-phase 
RPC    rotational planar chromatography 
SAR    structure-activity relationship 
syn.    synonym 
CTO    Communal Territory of Origin 
TEER    transendothelial electrical resistance 
TLC    thin layer chromatography 
VLC    vacuum liquid chromatography 
δ      chemical shift 
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1. INTRODUCTION 
The use of medicinal plants for treating illnesses is a worldwide phenomenon that is seen 
even nowadays from the native people of developing countries to the citizens of the largest 
metropolises. The traditional knowledge of medicinal plants has led to the development of 
various medicaments, and is still the basis of many scientific studies.  
The South-American rainforests are rich sources of traditional medicines based on a large 
variety of plants, and the aim of my work was therefore to conduct ethnopharmacological 
fieldwork in the Amazon. Porvenir is a Bolivian indigenous community in the Bajo Paraguá 
Communal Territory of Origin (CTO), home to the Chiquitano mestizos and the Guarasug’we 
indigenous nation, which is currently close to extinction. This region provided a good 
research area, because no ethnomedicinal fieldwork had previously been conducted in 
Porvenir.  
Numerous South-American plant species are traditionally used for central nervous system 
(CNS) disturbances, which are at the main focus of neuroscientific research, and therefore we 
aimed a phytochemical and pharmacological investigation of traditionally used plants with 
possible effects on the brain. From ethnopharmacological considerations, Lepidium meyenii 
and Heliopsis helianthoides var. scabra were chosen for detailed analysis. The hypocotyls of 
L. meyenii (Maca, Brassicaceae) are widely consumed as a common vegetable and have a 
multiplicity of other uses in the Peruvian and Bolivian highlands, among them fertility 
enhancement being the most popular. Maca has been found to contain certain metabolites 
characteristic of the species, such as the N-alkylamide (NAA) macamides. Some species of 
the Heliopsis genus (Asteraceae) are also used in North-American traditional medicines, and 
have been reported to contain NAAs and lignans. Among these species, H. helianthoides var. 
scabra has not been studied in detail. With the discovery of the functional interaction of plant 
NAAs with the endocannabinoid system (ECS), these compounds have become important as 
lead compounds of drug development. The promising anti-metastatic potential of several 
lignans underlines the significance of these compounds as potential tools in cancer treatment. 
Our studies on L. meyenii and H. helianthoides var. scabra focused on the phytochemical 
analysis of these species to isolate and identify NAAs and lignans and to carry out detailed 
pharmacological analyses to reveal their role in the folk medicinal applications of the plants 
and as potential tools in modern medicine.  
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The traditional knowledge of medicinal plants is also utilized in the food industry. Certain 
South-American plants, such as Maca are marketed in Europe, but their utilization partially 
differs from the traditional way. This difference raises the suspicion that the quality of certain 
products cannot meet the requirements, and an analytical study of Maca containing 
preparations was therefore also proposed. 
 
2. AIMS OF THE STUDY 
The aims of our study were 
 to describe the medicinal plants applied in the traditional medicine of Porvenir, 
Bolivia, and to find plant species which may be worthy of further phytochemical and 
pharmacological investigations on the CNS, by comparison of the folk-medicinal use 
with the available scientific literature data; 
 the isolation and structure elucidation of alkamides from L. meyenii and H. 
helianthoides var. scabra and, in the frame of cooperation, to test these compounds on 
different targets within the ECS; 
 the isolation and structure elucidation of lignans from H. helianthoides var. scabra 
and, in the frame of cooperation, to evaluate their potential antimetastatic activity in 
the brain; 
 to develop an analytical protocol for the qualitative and quantitative analysis of L. 
meyenii-containing food supplements and to screen selected products for the presence 
of synthetic adulterants (phosphodiesterase inhibitors).  
 
3. LITERATURE OVERVIEW 
3.1. ETHNOPHARMACOLOGICAL BACKGROUND  
Ethnopharmacological studies in South America comprise part of the age of the discovery of 
the continent. Adventurers in the New World, missionaries, and later anthropologists and 
botanists recorded the utilization of the plants, the scientific background of which started to 
be investigated decades or centuries later. Thanks to the researches and expeditions in the last 
two centuries, a good number of pharmacons have been developed from the plants and 
animals of the South-American rainforests.  
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In Bolivia, there are 37 indigenous groups
1
 and numerous mestizo communities living in 
different natural areas of the country, e.g. Altiplano, Yungas, Chaco or the tropical rainforest 
lowlands. Some general studies have been carried out on useful plants, including the 
medicinal species, especially from the Andes.
2,3
 In the highlands, there are mainly two 
indigenous cultures, the Aymara and the Quechua, representing 55% of the Bolivian 
population,
1
 both with great background knowledge on medicinal plants.
4
 Medicinal plants 
are still widely used in the countryside, but also in the main Andean cities, since a 
considerable proportion of their populations arrived from Aymara and Quechua peasant 
communities and maintain much of their own cultures.
4
 The Kallawaya medicine is the richest 
and best-known traditional medicine of Bolivia. More than a thousand medicinal plants and 
animal species and minerals used by Kallawaya healers were described by Girault,
5
 who 
provided a broad picture of the traditional healing capacities in the Andean area.  
Several ethnobotanical studies have been conducted in the Bolivian tropical rainforest 
lowlands,
6–9
 the subtropical Yungas,
10
 the dry region of Chaco,
11
 and the semi-deciduous 
forests of Chiquitanía.12 There have been numerous unpublished studies, and theses and 
dissertations accessible only at the local universities, on the ethnobotany of the indigenous 
nations and mestizo communities of Bolivia (e.g. theses from the Universidad Autónoma 
Gabriel René Moreno13–18). 
The ethnopharmacological study presented in this thesis was conducted in the Amazonian 
Porvenir, which is one of the five indigenous communities in the Territorio Comunitario de 
Origen Bajo Paraguá (Bajo Paraguá Communal Territory of Origin (CTO)) in Velasco 
Province, County of Santa Cruz, Bolivia (Figure 1). The flora of the CTO has not been 
studied thoroughly; there are data only on the flora of the Noel Kempff Mercado National 
Park, which borders on the CTO, and which is one of the most extensive ecological 
reservations in the world, with a surface of 1 523 446 hectares. 2705 plant species have been 
described in the national park, but a total of around 4000 species are estimated to be native to 
the area.
19
 One ethnobotanical work has been published on the region,
9
 with information 
concerning 36 medicinal plants used in 4 of the communities, with the exception of Porvenir. 
Moreover, ethnobotanical thesis work conducted in one of the communities (Bella Vista) 
noted 111 medicinal plant species, without discussing their indications.
15
 
The 378 163 ha of Bajo Paraguá hauses a population of about 1224 people, living in 4 
widely separated settlements (Piso Firme, Cachuela, Porvenir and Florida); the 519 of them 
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who live in Porvenir are mostly Chiquitano mestizos and some Guarasug’wes.20 All of them 
speak Spanish, and have a passive linguistic knowledge of Guarasug’we or Chiquitano. The 
Guarasug’wes (or Pausernas) are currently close to extinction: there are altogether only 31 
Guarasug’we inhabitants in 2 communities, 
Porvenir and Bella Vista.  
Porvenir is a semi-isolated community, the 
inhabitants of which partly live according to 
their traditional roots,
21
 but also benefit from 
the external world. The nearest relatively large 
settlement, San Ignacio de Velasco, with about 
23 000 inhabitants, is roughly 12 h away by 
coach. The CTO is located on the border of the 
tropical rainforests and the cerrado biome, the 
vegetation therefore being typical of the south-
west Amazonian forest and the inundated 
savanna. Porvenir is situated on the border of 
the rainforest, which is secondary woodland, 
and the savanna, close to the Paraguá River, 
and thus the locals can easily benefit from the 
natural resources provided by these 
ecosystems. 
Figure 1. Location of the study
*
.  
Although the traditional medicinal system of the community of Porvenir was previously 
described in detail by me,
22
 in the thesis I only focus on the plants used for CNS disturbances. 
As the phytochemical and pharmacological investigations of traditionally applied medicinal 
plants is usually more efficient, I chose the Maca plant from the Bolivian traditions, which 
has as well a modern widespread application in Europe. The second plant, a Heliopsis species 
selected for my Ph.D. work belongs to the North-American traditional medicine, and 
available in Hungary too. Its similar phytochemical profile, which presents NAAs with 
possible action to the CNS, links it to the first species. My aim was to scientifically analyse 
                                                          
*
 Geographical coordinates of Porvenir: 13°59’13” S, 61°32’30” W. The map of the Amazon was made with the 
use of the map downloaded from the web page of the Amazon Tour, and the map of Bajo Paraguá was made 
with the use of the map from the book 
9
. 
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plant species with possible CNS effects, starting with an evaluation of traditional applications, 
followed by phytochemical analysis and pharmacological investigations, and problems of 
modern consumption.   
3.2. BOTANY OF THE LEPIDIUM AND HELIOPSIS GENERA AND THE 
INVESTIGATED SPECIES 
3.2.1. Botany of the Lepidium genus and L. meyenii Walp. 
The Lepidium genus belongs to the Brassicaceae family, order of Brassicales, superorder of 
Rosanae, subclass of Magnoliidae, Equisetopsida class, Angiospermatophyta subdivision, and 
Spermatophyta division.
23
 
The Brassicaceae family, which contains very important crop plants, comprises 
approximately 3000 species. The genus Lepidium is the largest genus of the family, with 
approximately 175 species, which are widely distributed throughout the world in all 
continents except Antarctica. There are 4 cultivated Lepidium species: the worldwide known 
L. sativum L. (or garden cress); L. latifolium L. (dittander) and L. virginicum L. (poor man’s 
pepper), whose leaves are used as salad components; and L. meyenii Walp., known as Maca 
or Peruvian ginseng, the only species in the entire genus that produces fleshy roots.
24,25
 Maca 
was probably domesticated in the Department Junín, Peru, between 1300 and 2000 years ago, 
but little is known about its origin. Today, the species is mainly cultivated in the Andes of 
Peru and Bolivia at elevations of 3500-4450 m above sea level. Based on morphological 
observations and comparative analyses G. Chacón attempted to separate the species from its 
wild type, renaming the cultivated species L. peruvianum G. Chacón as a new species. 24 
However, this change was not accepted, and nowadays the name L. peruvianum is a synonym 
for L. meyenii
26
 Furthermore, a search for the wild type of the species identified 3 wild plants 
(L. bipinnatifidum Desvaux, L. kalenbornii C. L. Hitchcock and L. chichicara Desvaux) in the 
Andes, none of them closely related to Maca.
24
 
The Maca plant is a rosette of 12-20 frilly leaves with an enlarged fleshy underground 
storage organ formed by the taproot and the lower part of the hypocotyl, resembling a turnip. 
This is the economic product of Maca; for simplicity, it is called ‘hypocotyl’.24 It is about 10–
14 cm in length and 3–5 cm in width.25 13 hypocotyl color types are known, the black, yellow 
and red types being the most frequently used.
27,28
 The foliage forms a mat, growing in close 
contact with the ground. The leaves exhibit dimorphism, being larger in the vegetative phase 
and reduced in the reproductive cycle. The plant grows in a habitat of intense cold, extremely 
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intense sunlight, and strong winds. It is an annual crop completing its life cycle within a year 
when climatic conditions are favorable. The seeds have no dormancy, and germinate in 5–7 
days at 25 °C under good moisture conditions. A single plant of Maca produces 
approximately 14 g of seeds.
24
 
3.2.2. Botany of the Heliopsis genus and H. helianthoides var. scabra ‘Asahi’ 
The Heliopsis genus belongs to the Asteraceae (Compositae) family, order Asterales, 
superorder Asteranae, subclass Magnoliidae, Equisetopsida class, Angiospermatophyta 
subdivision and Spermatophyta division.
29
 
The Compositae family has more than 23000 species spread across 1620 genera; among 
them, the Heliopsis genus is represented by only 13 species, all of which are restricted to 
North, Central and South America. The plants in the genus are similar in appearance and 
closely related to those in the genus Helianthus, the sunflowers. Heliopsis is commonly called 
false sunflower.
30
 
H. helianthoides (L.) Sweet, a species commonly called smooth oxeye or false sunflower, 
is an upright, clump-forming, nearly glabrous, sunflower-like, short-lived perennial that is 
native to eastern and central North America. The subspecies H. helianthoides var. scabra 
(Dunal) Fernald differs from the species by having hairy and rough-textured (scabrous) leaves 
and stems with the leaves being thicker. The upper leaves may be entire, with the basal leaves 
toothed. Cultivars of var. scabra are more commonly grown in gardens than the species 
itself.
30
 H. scabra is a synonym for H. helianthoides var. scabra.
29
 Several cultivars are 
available with different flower colors and shades; one of them is ‘Asahi’, with bright-yellow 
double daisy-like flowers on sturdy stems.
31
 
3.3. TRADITIONAL AND MODERN USES OF THE INVESTIGATED SPECIES 
The dried and cooked hypocotyl of L. meyenii is consumed as a common vegetable and also 
used traditionally for medicinal purposes, as a general invigorator and as a fertility enhancer 
for human use and for domesticated animals
24,27,28
 Although Maca is not used traditionally for 
the improvement of CNS symptomes, Peruvian natives have observed more recently that the 
ingestion of the plant helps children in their school work.
27
 
Sexual performance and fertility enhancement are the most popular contemporary 
applications of Maca in Europe. However, there are several preparations that are claimed to 
increase mental and physical performances too. The number and variety of industrial products 
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(predominantly dietary supplements, mono- and multicomponent Maca preparations) on the 
European herbal market (mainly sold via the internet) are increasing.
24,32
  
Some species of the Heliopsis genus have been used by North-American Indians as 
medicinal plants. One of the most widely applied species, H. longipes (A. Gray) Blake, has 
been used to relieve toothache, and for the treatment of inflammations and ulcers. The root of 
H. helianthoides has been applied by the Meskwaki Indians to relieve lung troubles, and by 
the Chippewa Indians to strengthen limbs.
33
 Members of the Heliopsis genus are cultivated 
almost worldwide as ornamental plants. 
3.4. CHEMISTRY OF THE HELIOPSIS AND LEPIDIUM GENERA AND THE 
INVESTIGATED SPECIES 
3.4.1. N-Alkylamides 
Plant-derived NAAs or alkamides are lipophilic substances, a heterogeneous class of 
structurally different molecules. These compounds mostly contain a polyunsaturated aliphatic 
fatty acid chain and a shorter substituent on the amine side. Both substituents may include 
cyclic systems and/or heteroatoms (nitrogen, sulfur or oxygen). 
NAAs have been identified in 26 plant families, and are characteristic of certain 
Asteraceae species, especially in the genera Achillea, Acmella, Echinacea, Heliopsis and 
Spilanthes, and in some species of the plant families Brassicaceae, Piperaceae, Rutaceae and 
Solanaceae.
34
 To date, around 400 NAAs have been identified, more than 70 of them in the 
Heliantheae tribe (Asteraceae).
35,36
 Typical examples of an aliphatic NAA from Echinacea 
purpurea (L.) Moench
37
 and the aromatic ring-containing capsaicin from Capsicum annuum 
L. can be seen in Figure 2. 
                
 
 
dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide     capsaicin     
 
Figure 2. Two main types of plant N-alkylamides 
3.4.1.1. N-Alkylamides from Lepidium meyenii 
In the Brassicaceae family, some NAAs have been described from Arabidopsis thaliana and 
Brassica oleracea, and a large variety have been found in L. meyenii.
35
 The unsaturated fatty 
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acid amides, the alkylamide macamides are typical markers of the Maca plant. To date, 19 
macamides have been described
38–41
 (see in Annex 1). 
3.4.1.2. N-Alkylamides from the Heliopsis genus and H. helianthoides var. scabra 
Spilanthol (deca-2E,6Z,8E-trienoic acid isobutylamide, syn. affinin) is the best-known NAA 
in several Spilanthes species and, together with homospilanthol (deca-2E,6Z,8E-trienoic acid 
2-methylbutylamide)
42
, can be found in H. longipes (A. Gray) Blake. Undeca-2E,4E-diene-
8,10-diynoic acid isobutylamide, undeca-2E-en-8,10-diynoic acid isobutylamide and N-
isobutyl-2E-decenamide
43
 have also been reported from H. longipes. As compared with the 
alkamides of H. longipes bearing 1-3 double bonds, H. buphthalmoides (Jacq.) Dunal and H. 
helianthoides (L.) Sweet contain C18 NAAs with the rarely occurring pentaene acids. 
Octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid isobutylamide, octadeca-2E,4E,8E,10Z-
tetraen-12-ynoic acid isobutylamide, tetradeca-2E,4E,10Z-trien-8-ynoic acid isobutylamide 
and octadeca-2E,4E,8E,10E,14Z-pentaen-12-ynoic acid isobutylamide have been isolated 
from H. buphthalmoides, and the latter compound also from H. helianthoides.
44
 Two NAAs, 
scabrin (octadeca-2,4,8,10,14-pentaenoic acid isobutylamide) and heliopsin (octadeca-
2,4,8,10,12,16-hexaenoic acid isobutylamide or octadeca-2,4,8,12,14,16-hexaenoic acid 
isobutylamide) have also been identified  from H. scabra.
45,46
 The structures of the 
compounds are given in Annex 2. 
3.4.2. Lignans 
The lignans are a large group of phenolic compounds: nearly 500 lignan structures have been 
identified from plants so far.
47
 These compounds are present in many edible plants, such as oil 
seeds, seaweed, whole grains, fruits and vegetables.
48
 Some of the edible plant lignans, e.g. 
secoisolariciresinol and matairesinol isolated from flaxseed
48
 or hydroxymatairesinol from 
Picea abies,
49
 are converted by the intestinal bacteria to enterolignans, enterodiol and 
enterolactone, the latter of which is thought to be one of the major biologically active lignans 
in the human organism (Figure 3).  
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matairesinol      enterolactone     enterodiol 
Figure 3. Structures of the plant lignan matairesinol and 2 enterolignans derived from it 
3.4.2.1. Lignans from the Heliopsis genus and the investigated species 
In the Heliopsis genus, a wide variety of lignans have been identified: the dibenzylbutane 
derivatives heliobuphthalmin, 8-hydroxyheliobuphthalmin, 7Z-7,8-dehydroheliobuphthalmin 
and 2-[(2H-1,3-benzodioxo-5-yl)methyl]-3-[(3,4-dimethoxyphenyl)methyl]succinic acid 
dimethyl ester; the dibenzylbutyrolactones heliobuphthalmin lactone and 5,7'-
dehydroheliobuphthalmin lactone in the aerial parts of H. buphthalmoides (Jacq.) 
Dunal;
44,50,51
 the dibenzylbutyrolactones hinokinin and 2′-hydroxyhinokinin in the stem of H. 
longipes (A. Gray) Blake.
43
 Two lignan derivatives, the dibenzylbutyrolactone helianthoidin 
and the arylnaphthalene helioxanthin, were isolated previously from the root of H. 
helianthoides var. scabra (Dunal) Fernald. 
52,53
 Lignans isolated from the genus are to be seen 
in Annex 3. 
3.4.3. Other compounds 
3.4.3.1. Other compounds from Lepidium meyenii 
The hypocotyls of L. meyenii contains alkaloids. 1R,3S-1-Methyltetrahydro-β-carboline-3-
carboxylic acid (MTCA) is found in several species,
54
 but the majority of the alkaloids found 
in Maca (macaridin, lepidilin A and B) have been identified only in this species.
28
 Other 
important secondary metabolites of L. meyenii are glucosinolates and their derivatives,
54,55
 
most of them containing an aromatic ring, e.g. glucotropaeolin, m-
methoxybenzylglucosinolate and benzylisothiocyanate.. 
Depending on the origin and color of the hypocotyl, the composition and quantity of the 
secondary metabolites of Maca may be very different,
27
 macaenes, macamides and 
glucosinolates differ substantially. Black and lead-colored Maca contain the largest quantity 
of glucosinolates, while yellow Maca is the richest source of macaenes, macamides and 
phenols.
56
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3.4.3.2. Other compounds from Heliopsis helianthoides 
Besides the alkamides and lignans, 13 guaianolides, 1 germacranolide, 3 derivatives of 
homogeranylnerol, 1 daucane and 1 tremetone derivative have been reported from H. 
helianthoides previously.
44,57
 
3.5. PHARMACOLOGY OF THE INVESTIGATED SPECIES AND THE RELATED 
COMPOUNDS 
3.5.1. Pharmacology of the N-alkylamides 
NAAs are present in some plants, where these compounds exert growth regulatory functions, 
similarly to N-acylethanolamines.
58
 Various bioactivities of plant-derived NAAs have been 
described in mammalian tissues, such as antimicrobial and related activities, effects on anti-
inflammatory and immunomodulatory processes, and activity on the ECS.
35
  
3.5.1.1. Antimicrobial activities 
Numerous studies have dealt with the antibacterial and antifungal, and also the antiparasitic, 
molluscicidal and insecticidal activities of NAAs.
35
 The antibacterial effects of several NAAs 
against Escherichia coli, Pseudomonas solanacearum, Erwinia carotovora, and Bacillus 
subtilis were studied by Molina-Torres et al.
59–61
 
The minimal inhibitory concentrations of the investigated NAAs for E. coli, P. 
solanacearum and E. carotovora range between 5 and 300 μg/mL.59 Those of 4 
phenylethylamides for the Gram-positive bacterium B. subtilis were 10-150 μg/mL; all of 
them reached more than 90% of inhibition.
61
 The degree of unsaturation and the chain length 
of the acid moiety influences the growth inhibition of B. subtilis. The amide moiety impacts 
the inhibitory effect, phenylethylamides generally exhibiting higher activities, than those of  
isobutylamides.
35
 Affinin isolated from H. longipes inhibited the growth of E. coli and S. 
cerevisiae at concentrations as low as 25 mg/mL. Higher concentrations of affinin were 
necessary to inhibit the growth of P. solanacearum and B. subtilis.
59
 
Antifungal effects of several NAAs have been studied against Sclerotium rolfsii, 
Cladosporium sphaerospermum and C. cladosporioides.
60,62
 Penta-2E-ene-5-
(benzo[1,3]dioxol-5-yl) acid pyrrolidide and penta-2E,4E-ene-5-(benzo[1,3]dioxol-5-yl) acid 
pyrrolidine were the most active, with minimal inhibitory concentrations of 10 μg/mL. A 2E 
unsaturation in the acid or the amine side-chain was generally favorable for fungal growth 
inhibition. NAAs possessing a sulfur atom in their acid or amine moieties displayed increased 
12 
 
antifungal effects. In straight-chain acid isobutylamides such as affinin, the 2E,6Z,8Z 
unsaturation was necessary for fungal inhibition.
35
 The 2E and fully unsaturated affinin 
derivatives pellitorine and fagaramide, isolated from Zanthoxylum gilletii (De Wild.) P.G. 
Waterman, were ineffective against fungal growth.
63
  
The antiplasmodial activities of some NAAs have been evaluated. Lemairamide and 
zanthomamide isolated from Z. rubescens Planch. ex Hook. f. (Rutaceae) exerted weak 
activity, with average IC50 values ranging from 45.6 μM to 149.9 μM.
64
 Pellitorin and 
fagaramide were more active, with IC50 values of 24.1 μM and 50.0 μM, respectively.
63
 It was 
suggested that the α,β-unsaturated carbonyl function rather than the N-isobutyl substituent is 
the responsible active site. 
63,64
.  
3.5.1.2. Anti-inflammatory and immunomodulatory activities 
The anti-inflammatory and immunomodulatory properties of Echinacea species have been 
well investigated, confirmed and patented.
35,65–68
 Further, the immunomodulatory effects of 
Anacyclus pyrethrum and the anti-inflammatory effects of Spilanthes, Heliopsis, Piper and 
Achillea species have also been established.
36
 Affinin inactivates nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB), shows significant topical anti-inflammatory 
effects in the mouse ear edema test and is the only NAA that has a proved influence on the 
transcription and translation of the cyclooxygenase enzymes, which play roles in 
inflammatory processes.
36
 
3.5.1.3. Analgesic and anticonvulsant effects 
The dichloromethane extract of H. longipes has been shown to exert an analgesic effect, 
which may be attributed to the alkylamide content of the root and especially to affinin.
43
 
Affinin also demonstrates an antinociceptive effect,
69
 modifies anxiety behaviour, prolongs 
the duration of sodium pentobarbital-induced hypnosis, and decreases the time of clonic and 
tonic pentylenetetrazol-induced seizures in rats.
70
 
3.5.1.4. Activity on the endogenous cannabinoid system 
With the discovery of the functional interaction of NAAs with the ECS,
66–68,71–73
 a new 
pharmacological mode of action of medicinal and food plants containing N-acylethanolamines 
was revealed. In mammalian tissues, different NAAs from medicinal plants exert analgesic, 
anti-inflammatory and immunomodulatory effects, potentially also via the ECS.
65,74
 For 
instance, NAAs seem to play a major role in the bioactivity of the widely used medicinal 
plants of the Echinacea genus.
35,65–68
 The immunomodulatory Echinacea alkylamides dodeca-
13 
 
2E,4E,8Z,10Z-tetraenoic acid isobutylamide (Figure 2) and dodeca-2E,4E-dienoic acid 
isobutylamide bind to the cannabinoid-2 (CB2) receptor more strongly than the endogenous 
cannabinoids.
68
 While the interactions of Echinacea NAAs with CB receptors have been 
studied in more detail, ECS-interacting NAAs from other plants have been described only 
recently.
72,73,75,76
 The assumption that NAAs may interfere with the ECS due to their 
structural similarity to endocannabinoids such as anandamide (N-arachidonoylethanolamide, 
AEA) and palmitoylethanolamide
35
 is intuitive, but the confirmation of this assumption is 
hampered by the lack of structure – activity relationship (SAR) data.  
 
   anandamide (AEA)  
 
Chemically diverse plant NAAs showing different saturation patterns and double bond 
configurations therefore provide a source for further analysis of the ECS-binding interactions 
of this class of natural products. Moreover, insights from such studies may inspire the 
generation of scaffolds for the development of novel chemical probes or may explain the 
traditional use of certain plants. 
3.5.2. Pharmacology of lignans  
Several bioactivities of lignans have been described, such as antimicrobial and antiviral 
activities, anti-inflammatory and immunosuppressive, hepatoprotective effects, roles in 
osteoporosis and cancer prevention, and antitumor activities.
77
 Only the antitumor and the 
related antimetastatic activities are discussed here.  
3.5.2.1. Antitumor and antimetastatic activities 
Experimental evidence has demonstrated clear anticarcinogenic effects of enterolignans,
78
 
lignan-containing flaxseed extracts
78
 or pure lignans such as hydroxymatairesinol
49
 and 
honokiol
79,80
 in animals. A number of investigations have revealed the cytostatic effects of 
numerous lignans on different types of cancer cells.
81–89
 Certain compounds, including 
schizandrin B,
84
 picropodophyllin,
85 
podophyllotoxin and their derivatives,
90
 display marked 
anticancer and antimetastatic activities.  
One of the possible strategies to prevent tumor angiogenesis is to inhibit endothelial cell 
migration into the tumor. Interestingly, the angiogenic effects of secoisolariciresinol 
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diglucoside, isolated from the flaxseed,
91
 and sesamin, naturally present in sesame oil,
92
 have 
been proved. Nevertheless, another study indicated the antiangiogenic property of honokiol 
because of the pronounced downregulation of vascular endothelial growth factor (VEGF) and 
intercellular adhesion molecule 1 (ICAM-1) in H1299 human lung adenocarcinoma cells 
treated with this lignan.
93
 Various lignans have been demonstrated to downregulate different 
matrix metalloproteinases
80,84,94
 and cellular adhesion molecules,
95–98
 such as vascular cell 
adhesion molecule-1 (VCAM-1) and ICAM-1, which are considered to be important in the 
extravasation of tumor cells. Moreover, treatment with different lignans reduces the migratory 
potential of highly metastatic tumor cells.
94,99
 However, the effects of lignans on the 
transmigration of metastatic cells through endothelial barriers (a critical step in metastasis 
formation) have not been investigated so far. 
3.5.3. Pharmacology of Lepidium meyenii 
Numerous studies have been carried out with the hypocotyl of Maca, such as investigations 
on its sexual activity and fertility enhancement effects, antioxidant and antiproliferative 
functions, adaptogenic effects, and activities on postmenopausal osteoporosis and the 
CNS.
25,27,28
 Only the studies conducted on its activities on the CNS, and its sexual activity and 
fertility enhancement effects are discussed here. 
In vivo experiments on rats and mice have shown that a boiled aqueous or hydroalcoholic 
extract of the black variety of Maca helps studying, improves memory and has a positive 
effect in scopolamine-induced memory impairment.
100–102
 Black Maca inhibited 
acetylcholinesterase in ovariectomized mice, and it is therefore proposed that it improves 
experimental memory impairment.
27
 MTCA isolated from Maca acts as an inhibitor of the 
enzyme monoamine oxidase.
54
 However, Gonzales et al. have proven that MTCA as a 
component of Maca extracts does not inhibit monoamine oxidase.
103
 
It has been shown that the macamide N-3-methoxybenzyl linoleamide weakly inhibits the 
major AEA degrading enzyme fatty acid amide hydrolase (FAAH, which is a membrane 
bound mammalian enzyme responsible for the destruction of a number of endogenous 
signaling amides by hydrolysis), and may thus exert indirect cannabimimetic neuroprotective 
effects.
75
 This was recently confirmed in a study in which synthesized macamides and analogs 
were shown to act as FAAH inhibitors, although no further ECS targets were tested.
76
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In some pharmacological experiments, the sexual behaviour of male rats and the erectile 
function of castrated rats were enhanced.
104,105
 In a similar experiment, Maca was inactive, 
but the reason for this could be the much lower dosage.
106
  
Fertility-enhancing effects were observed in both male and female rats. The weights of 
the testicles and epididymis of healthy rats increased after the consumption of an aqueous 
extract of the plant, and the weight increase of the epididymis was considered to be related to 
an increase of the sperm count.
107–109
 The rate of spermatogenesis and the sperm motility also 
improved in healthy
110,111
 and pathological
107–109,112
 conditions. These parameters changed 
similarly in healthy bulls
113
 and in mice following spermatogenic damage induced by 
malathion.
114
 
In vitro
115
 and in vivo experiments suggest that Maca may have an estrogen-like effect, 
which may be related to the fertility improvement observed in female rats and mice. The 
uterus weight was increased in healthy mice fed with Maca,
100,116
 and the rate of osteoporosis 
in ovariectomized rats decreased, but an increase in uterus weight related to an estrogen effect 
was not observed in this case.
117
 The explanation for the contradictory estrogen-like effects 
may be the different compositions of the applied plant materials and the presence of selective 
estrogen receptor modulators in the plant, which behave as agonists or antagonists depending 
on the tissue. 
Maca consumption affects neither the estradiol level
109,111,117–120
 nor the plasma 
concentrations of testosterone, luteinizing hormone, follicle stimulating hormone and 
prolactin.
118
 Several reviews discuss whether the effects of Maca on the reproductive system 
may be due to the estrogen-like phytosterols of the hypocotyl,
28,115
 but this has been refuted 
by other studies.
121,122
 
Comprehensive phytochemical and pharmacological comparisons of hypocotyls from the 
different color types have not been performed to date in detail. The application of different 
hypocotyl color types could explain the contradictions in the pharmacological results. Red 
Maca decreases the prostate size, and provides prostatic hyperplasia even in the presence of 
testosterone, but this is not characteristic for yellow and black Maca. The latter increases the 
number of spermatides in the testes and the sperm count in the epididymis, but red Maca does 
not. The best reproductive character is attributed to the black type, followed by yellow and 
red Maca. The black one is also considered the best energy source and invigorator.
27,28
  
16 
 
The mechanisms involved in the reproductive system of Maca have not been revealed in 
detail so far. Examinations of different Maca extracts did not confirm androgen receptor 
binding,
123
 or changes in testosterone level,
111,120,124
 – with the exception of one study where 
the testosterone level of mice increased after Maca consumption.
119
 According to Gonzales, 
the potency-enhancing effect of Maca is not related to changes in depression or anxiety,
125
 
and is independent of its nutritive values.
105
 The current knowledge on the chemistry of L. 
meyenii indicates that macamides, alkaloids, glucosinolates and their derivatives, polyphenols 
and flavonoids may also take part in the pharmacological activities of the species,
56
 though 
their exact roles have not been elucidated so far. 
3.5.4. Pharmacology of Heliopsis helianthoides var. scabra 
Pharmacological investigations with extracts of this species have not been published, but 
several studies have been conducted with pure compounds isolated from it. 
The insecticidal activity of the NAAs scabrin and heliopsin has been demonstrated on 
house flies.
45,46
 The lignan helioxanthin inhibits hepatitis B virus gene expression and viral 
particle production in vitro,
126
 and also has some effect on the presumed molecular 
mechanisms of hepatic inflammatory disease.
127
 Its synthetic derivatives exhibit significant in 
vitro antiviral activity against various viruses, including hepatitis B and C and herpes simplex, 
and moderate activity against HIV.
128
 The compound displays cytotoxicity on an HeLa cell 
line.
89
 
Heliobuphthalmin exhibits high antineoplastic activities against the classical multidrug 
resistant subline derived from gastric carcinoma;
129
 and reduces the viability of hepatocellular 
carcinoma cells (HuH-7 cells) as a strong inducer of apoptosis.
130
 In contrast, 
heliobuphthalmin has been shown not to have cytotoxic activity on the human lung cancer 
cell line A549 and an inhibitory effect on human cytomegalovirus IE gene expression in A549 
cells,
131
 and does not show significant cytotoxic effects in vitro on human hepatoma and 
cervical carcinoma cell lines.
132
 It exerts weak in vitro activity against the 3D7 Plasmodium 
falciparum strain.
133
 Dehydroheliobuphthalmin has significant neuroprotective activity 
against glutamate-induced neurotoxicity.
134
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3.7. TOXICOLOGY OF THE INVESTIGATED SPECIES 
3.7.1. Toxicology of Lepidium meyenii 
Review data on in vivo and in vitro studies with Maca indicate that its use is safe.
27
 According 
to a study based on questionnaires and laboratory investigations (liver and kidney function 
and blood profile) with 600 Peruvian participants, Maca consumption is safe and the health 
status of Maca-consuming people is high.
135
 
3.7.2. Toxicology of Heliopsis helianthoides var. scabra 
No studies are available on the toxicity of the species. The related H. longipes has been shown 
in an acute toxicity study on mice to be non-toxic (LD50=288 mg ethanol extract/kg).
136
  
3.8. CLINICAL STUDIES OF LEPIDIUM MEYENII 
The effects of the species on sexual function and fertility in humans have been studied by 
many groups. A systematic review
137
 of 7 studies on sexual function found that only 4  
randomized trials met all their inclusion criteria, in which 1.5-3.5 g dry Maca powder was 
given orally daily to 8-57 participants for 4-6 weeks. Consumption of the hypocotyl has been 
found effective in mild erectile dysfunction,
138
 and to improve sexual desire in healthy 
man,
125
 and positive psychological changes have been observed in menopausal women.
120
 A 
study including the examination of the  physical performance-enhancing effect of the plant 
(performed with only 9 participants) showed slightly enhanced sexual activity, but changes in 
sport achievements were not observed.
139
 In another study with 9 participants (but without a 
control group), the number and motility of spermatocytes was approximately doubled when 
the dry powder was consumed in daily dosages of 1.5-3 g during 4 months.
107
 Overall, the 
numbers of participants were too low, and the studies were too heterogeneous to allow 
appropriate conclusions.  
3.9. FOOD SUPPLEMENTS 
The term food supplement
*
 was defined in 1994, and practically covered preparations of 
minerals and vitamins of good quality at the beginning, but increased commerce in 
preparations containing materials of herbal or animal origin has become a worldwide 
phenomenon in the last decade.
140
 The public opinion that these products are natural and 
                                                          
*
“Food supplements means foodstuffs the purpose of which is to supplement the normal diet and which are 
concentrated sources of nutrients (vitamins, minerals) or other substances with a nutritional or physiological 
effect, alone or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills 
and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar forms 
of liquids and powders designed to be taken in measured small unit quantities”176  
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hence safe plays an important role in their increased consumption. Due to the lack of proper 
quality control in some cases, however, the declared and the real compositions of the products 
may differ, and certain products contain non-labelled substances, including synthetic 
compounds, to enhance the effect. Adulteration is particularly frequently in the case of 
products marked as potency enhancers.
141
 Since the male sexual performance-enhancing 
effect of L. meyenii and its metabolites has not been confirmed convincingly either 
preclinically or clinically, Maca products marketed for this purpose are candidates for quality 
control, focusing on activity-potentiating synthetic compounds. In the frame of the research, 
the quality control of 14 namely Maca-containing products has been carried out.
32,142
 
 
4. MATERIALS AND METHODS 
4.1. ETHNOPHARMACOLOGICAL METHODS 
4.1.1. Fieldwork 
My fieldwork was conducted for 5 months between September 2004 and June 2005, in two 
phases, partly in the dry and partly in the humid season. The first month involved 
familiarization with the field, and participant observation and informal interviews with the 
inhabitants, which was important in order to establish the basis of cooperation. A total of 16 
adults from 16 different families were selected to participate in semi-structured interviews 
with open questionnaires. The information recorded included personal data, the vernacular 
names of the medicinal plants used in Porvenir, the parts used, the plant habits, the modes of 
preparation and application, the formulas, the doses and the therapeutic purposes. Two 
samples of each plant were collected with the participation of the interviewed subjects. The 
specimens were dried in Porvenir with the aid of a hand-made drying box, utilizing the heat of 
the fireside in a kitchen. 
4.1.2. Identification of plants 
Voucher specimens were deposited at the National Herbarium of the Noel Kempff Mercado 
Natural History Museum in Santa Cruz, Bolivia, where they were botanically identified, using 
handbooks and by comparison with the specimens in the Herbarium, and with the help of the 
taxonomists of the Museum. 
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4.1.3. Ethnobotanical data analysis 
The knowledge of the inhabitants on medicinal plants was analyzed by means of the modified 
method of Gentry and Phillips,
143,144
 which assesses the frequency and the variety of use of 
plants. The frequency of use was determined from the number of people interviewed who 
used the given species, while the variety of use involves the number of different diseases that 
can be treated with the given species. 
4.1.4. Scientific data collection and data analysis 
Ethnobotanical, chemical and pharmacological data were collected from the following 
databases: SciFinder Scholar, Web of Knowledge, Science Direct, PubMed and Scopus up to 
2012. Additionally, ethnobotanical data were gathered from Bolivian university dissertations, 
ethnobotanical books, journals and relevant web pages. The data found in the literature were 
compared with the application in Porvenir. Mainly the following points were taken into 
consideration: (1) whether the given species was used in a similar way in other regions, 
countries or traditional communities, (2) whether chemical components were described, and 
(3) whether the described pharmacological effects support the application in Porvenir. 
4.2. PLANT MATERIAL  
The roots of H. helianthoides var. scabra (Dunal) Fernald ‘Asahi’ were obtained from a 
nursery (Hegede Flower Nursery Ltd., Kecskemét, Hungary) in the flowering period in 
September 2009. A voucher specimen (No. 819) has been preserved in the Herbarium of the 
Department of Pharmacognosy, University of Szeged, Szeged, Hungary. The plant material 
was washed, cleaned and processed in a fresh form. 
The yellow dry hypocotyl powder of L. meyenii Walp originated from Peru and was 
purchased from Raw Organic Maca Powder, EverTrust Ltd, UK (batch number M-010177-
11-220312). The material was stored at room temperature until preparation. A representative 
sample (No. 823) is available at the Department of Pharmacognosy, University of Szeged, 
Szeged, Hungary. 
4.3. PURIFICATION AND ISOLATION OF COMPOUNDS 
For vacuum liquid chromatography (VLC), SiO2 (silica gel 60 GF254, 15 µm, Merck) and 
reversed-phase (RP) SiO2 (LiChroprep RP-C18, 40-63 µm, Merck) were applied. Separations 
were monitored by thin layer chromatography (TLC) (aluminum sheets coated with silica 
gel 60 F254, 0.25 mm, Merck 5554 and silica gel 60 RP-C18 F254s, Merck). The chromatograms 
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were visualized at 254 and 366 nm, and by spraying with concentrated H2SO4, followed by 
heating at 110 °C.  
Medium pressure liquid chromatography (MPLC) was performed with a Büchi apparatus 
(Büchi Labortechnik AG, Flawil, Switzerland), using a 40 × 75 mm RP18ec column (Büchi, 
40-63 µm).  
Preparative thin-layer chromatography (PLC) was carried out on silica gel 60 F254 (0.25 
mm, Merck).  
Rotational planar chromatography (RPC) was performed with a Chromatotron instrument 
(model 8924, Harrison Research, Palo Alto, CA, USA) on manually coated SiO2 plates (silica 
gel 60 GF254, Merck 7730).  
High pressure liquid chromatography (HPLC) experiments were carried out on a Young-
Lin 9100 series HPLC system (Young-Lin, Korea), equipped with a UV detector and on-line 
degasser using an RP-C18 column (YMC-Pack ODS-A 250 × 4.6 mm, 5 µm, 120 Å, YMC, 
Germany) at 30 °C and on a Waters 600 system (Waters Corporation, Milford, USA), 
equipped with an UV detector and on-line degasser using a RP C18 column (LiChroCART 5 
μm, 100 Å, 250 × 4 mm column, Merck KGaA, Darmstadt, Germany) at 25 °C.  
Centrifugal partition chromatography (CPC) was carried out on Armen SCPC apparatus 
(Armen Instrument Sas, Saint-Avé, France) equipped with a gradient pump, a 10 mL sample 
loop, an ASC/DSC valve, a 250 mL column, a UV detector, and an automatic fraction 
collector. The system was controlled by Armen Glider software.  
4.4. CHARACTERIZATION AND STRUCTURE ELUCIDATION 
Nuclear magnetic resonance (NMR) spectra were recorded in CDCl3 on a Bruker Avance 
DRX 500 spectrometer at 500 MHz (
1
H) or 125 MHz (
13
C). Two-dimensional (2D) data were 
acquired and processed with standard Bruker software. For 
1
H–1H COSY, HSQC and HMBC 
experiments, gradient-enhanced versions were used.  
Mass spectrometry (MS) was carried out in positive ionization mode with an API 2000 
MS/MS equipped with an atmospheric pressure chemical ionization (APCI) interface. The 
source temperature was 400 °C (H. helianthoides var. scabra samples) or 450 °C (L. meyenii 
samples). Data acquisition and evaluation were performed with Analyst 1.5.2 software. 
Optical rotation values were determined in CHCl3 at room temperature by using a Perkin-
Elmer 341 polarimeter. 
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4.5. PHARMACOLOGICAL TESTS WITH THE ISOLATED COMPOUNDS 
4.5.1. Evaluation of the isolated N-alkylamides in the endocannabinoid system 
Evaluation of the NAAs on the endocannabinoid system was carried out by Jürg Gertsch and 
his research group (Institute of Biochemistry and Molecular Medicine, NCCR TransCure, 
University of Bern, Bern, Switzerland). 
The isolated compounds were investigated on different targets of the ECS, including CB1 
and CB2 receptor binding, inhibition of FAAH, AEA transport, and monoacyl glycerol lipase 
(MAGL). The methods are described in detail in 
145
. 
4.5.2. Evaluation of antimetastatic effects of lignans in the brain 
Investigation of the pharmacological effects of the isolated lignans were performed by János 
Haskó and his colleagues (Institute of Biophysics, Biological Research Centre, Hungarian 
Academy of Sciences, Szeged, Hungary).  
In the first set of experiments, the isolated lignans were tested on the viability of cerebral 
endothelial cells and melanoma cells. The morphological changes and the effects on the 
migration of melanoma cells, phalloidin staining of the actin-cytoskeleton, the attachment of 
melanoma cells to brain endothelial cells, and improvement of the barrier function of the 
endothelial cells were then evaluated. Measurement of transendothelial electrical resistance 
(TEER) and a wound healing assay were also applied. The methods can be seen in detail in 
146
. 
4.6. QUANTIFICATION OF MACAMIDE CONTENT OF DIETARY 
SUPPLEMENTS 
4.6.1. Chemicals and reagents 
The macamide N-benzyl-(9Z,12Z)-octadecadienamide that we isolated was used as chemical 
marker. Peak purity analysis carried out with the Empower Pro software confirmed that the 
chromatographic peak of the compound was spectrally pure. Millipore Direct-Q UV3 clarifier 
(Millipore Corporation, Billerica, MA, USA) was used to obtain purified water for HPLC 
measurements. Synthetic phosphodiesterase inhibitors were isolated previously from 
adulterated dietary supplements (sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra); 
and their derivatives (pseudovardenafil, nor-acetildenafil, thiosildenafil, dimethyl-
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thiosildenafil, and aminotadalafil). Ten Maca-containing dietary supplements were purchased 
in Hungarian shops, 3 Maca powder samples were provided by Ashaninka Pharma Ltd. 
(Hungary), and 1 Maca powder was purchased in a webshop (UK). 
4.6.2. Sample preparation 
Dry Maca hypocotyl powder (Raw Organic Maca Powder, EverTrust Ltd, New Malden, UK, 
originating from Peru) was used for validation of the analytical method. 500 mg of the 
product was extracted with 10 mL n-hexane (10 min extraction in an ultrasonic bath at room 
temperature), then diluted with n-hexane to 25.0 mL in a volumetric flask and centrifuged (10 
min, 2500 rpm). 20.0 mL of the supernatant was pipetted into a round-bottomed flask and 
evaporated under vacuo. Extracts were redissolved in 2 mL of n-hexane, and filtered through 
a filter membrane (Acrodisc
®
 GHP 13 mm, 0.45 μm, Waters, USA). The first 0.5 mL was 
rejected; the other 1.5 mL was analyzed by HPLC-DAD. Three extracts were prepared and 
analyzed in triplicate.  
In the case of product quality analysis, 500 mg of the powder products and 380–1000 mg 
of the multicomponent preparations (depending on the tablet or capsule sizes) were processed 
as described above.  
4.6.3. Calibration and linearity 
As calibration standard, N-benzyl-(9Z,12Z)-octadecadienamide, a major alkamide of L. 
meyenii, was applied. In order to obtain the linear range of quantification, stock standard 
solutions (1.2 mg/mL) were prepared with n-hexane. 1.0 mL of the stock standard solution 
was transferred to a 10.0 mL volumetric flask and diluted with n-hexane. Different amounts 
of this solution were diluted with n-hexane to obtain 6 different concentrations in the range 
0.0048–0.06 mg/mL. The calibration range of N-benzyl-(9Z,12Z)-octadecadienamide was 
0.048–12.0 μg/injection. 10-μL of the standards were injected in triplicate. The slope, 
intercept and correlation coefficient were determined. For calculation of the calibration curve, 
peak areas were plotted against the injected mass of the macamide standard.  
4.6.4. HPLC apparatus and measurement conditions  
HPLC analysis was carried out on a Waters 600 system (Waters Corporation, Milford, USA), 
equipped with a 2998 photodiode array detector, an on-line degasser, a column thermostat and 
autosampler using a RP Kinetex XBC18 (2.6 μm, 100 Å, 100 × 4.6 mm column (Phenomenex, 
Torrance, USA) at 25 °C). Chromatographic elution of the samples was accomplished with an 
23 
 
isocratic solvent system consisting of MeCN–H2O 85:15 at a flow rate of 0.7 mL/min. For 
analysis, 10.0 μL of extract was injected. The samples were monitored at 210 nm. Data 
acquisition and evaluation were performed with Empower Pro software. 
4.6.5. Method validation 
Repeatability was evaluated via experiments with Raw Organic Maca Powder extracts. 
Intraday precisions were calculated from data acquired during a 3-day validation. Precision 
was expressed as relative standard deviation (RSD%). The signal to noise ratio was used to 
express the limit of detection (3 times the noise) and quantitation (10 times the noise). 
Recovery analysis was carried out by adding known amounts of macamide (64, 128 and 
256% of N-benzyl-(9Z,12Z)-octadecadienamide) to the Maca extract (n=3 at each 
concentration). To assess the stability of N-benzyl-(9Z,12Z)-octadecadienamide in the n-
hexane extract, the extracts were stored at room temperature and analyzed after 3 and 4 days. 
4.6.6. Detection of phosphodiesterase inhibitors 
For the presence of phosphodiesterase inhibitors, multicomponent preparations were analyzed 
by TLC and HPLC-DAD according to a protocol developed in our laboratory.
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 Briefly, 1 
capsule or tablet was extracted with 10 mL of MeOH for 10 min in an ultrasonic bath at room 
temperature, and then filtered through a membrane filter. 10 µL of the extract was applied to a 
silica gel stationary phase (Merck 105553 60, 20 × 20) and developed in toluene–Me2CO–
EtOH–25% NH3 (70:50:10:3) in a developing chamber saturated with solvent vapor. The 
development distance was 20 cm. The detection was performed under UV light (254 nm) and 
by spraying the plate with Dragendorff’s reagent or vanillin–sulfuric acid and heating at 120 
°C. This method allows the identification of phosphodiesterase inhibitors by comparing their 
retention factors and the colors of the spots with those of analytical standards. Selective 
detection with Dragendorff’s reagent gives a possibility for the detection of so far unidentified 
synthetic derivatives.  
For HPLC-DAD analysis, a Gemini-NX 5u C18 100A, 100 × 4.6 mm column was used. 
The solvent system was NH4HCO3 (10 mM, pH = 10.00±0.2) – MeCN (7:3) at a flow rate of 
1 mL/min. 20 µL of extract was injected. The samples were monitored in the whole UV range 
(200–400 nm) and at 220, 254, 282 and 292 nm. Data acquisition and evaluation were 
performed with Empower Pro software. Synthetic phosphodiesterase inhibitors can be 
identified via their retention times and characteristic UV spectra. 
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5. RESULTS 
5.1. ETHNOPHARMACOLOGICAL FIELDWORK 
Accounts of the lifestyle and beliefs in Porvenir, botanical data regarding the plants used, the 
diseases that occur and their possible treatment, methods of plant application, frequency and 
variety of use, and some species and formulas are discussed in detail in 
22
. The plants used for 
illnesses of the CNS, pain or fever are discussed here. A total of 145 medicinal plant species 
were registered in Porvenir, which are applied for 107 known complaints or symptoms. The 
latter are grouped in main categories in Table 1. 
 
Table 1. The use of the plants by illness categories 
Illness categories  
No. of 
indications 
No. of 
species 
Diseases of the alimentary tract and the metabolism 18 60 
Diseases of the CNS, pain and fever 11 37 
Diseases of the genitourinary tract 10 35 
Dermatological diseases 12 34 
Diseases of the respiratory system 7 32 
Infectious and parasitic diseases 9 30 
Diseases of the musculoskeletal system, traumatic injuries 9 28 
Pediatric diseases 6 10 
Diseases of sense organs 3 9 
Cardiovascular diseases 2 9 
Intoxications by animals 3 8 
Tumorous diseases 1 5 
Hematological diseases 2 4 
Other diseases and symptoms 8 17 
Total 101  
 
The CNS, pain and fever therapeutic area can be divided into 11 subcategories, in which a 
total of 37 species were used (Annex 4). Among these subcategories, headache (12 species) 
and fever, including Dengue-fever (12), were the most frequent. To alleviate toothache, 8 
plants were noted; 8 species were used against arrebato (probably stroke); “cold exudation” 
(2) probably appears in febrile stages; 4 species were used to relieve nervousness, 3 against 
sadness (melancholy), 2 for weight control, 2 for weakness, and 2 species for alcoholism. The 
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fieldwork disclosed 1 species for “keeping ghosts away”. The species and their indications 
can be found in Annex 4.  
5.2. ISOLATION OF THE COMPOUNDS FROM LEPIDIUM MEYENII  
Dried L. meyenii hypocotyl powder (1.2 kg) was extracted twice with n-hexane (30 °C, 
ultrasonic bath, 2 × 15 min, 2 × 3000 mL), filtered and then centrifuged. The supernatant was 
concentrated in vacuo, yielding 9 g of material, which was subjected in 4 parts to CPC, using 
a two-phase solvent system consisting of n-hexane–EtOAc–MeOH–H2O 9:1:9:1 (2200 rpm, 
12 mL/min flow rate, 60 min) in the ascending mode (CPC I). Nine main fractions (I–IX) 
were obtained, from which V (370 mg) and VI (235 mg) were purified again with CPC 
(MeCN–H2O, 1:1, descending mode, 2200 rpm, 12 mL/min flow rate, 60 min program, CPC 
II) and the alkylamide-containing fractions and main fraction VII (80 mg) were then subjected 
to HPLC (Young-Lin, semi-preparative RP-C18 column, MeCN–H2O, 9:1): three almost pure 
compounds were obtained, and the final purification was carried out by RP-HPLC (Waters, 
MeCN–H2O, 95:5), which resulted in the isolation of compounds 1 (1 mg), 2 (8 mg) and 3 (92 
mg). 
5.3. ISOLATION FROM HELIOPSIS HELIANTHOIDES VAR. SCABRA 
The fresh roots of H. helianthoides var. scabra ‘Asahi’ (9 kg) were extracted with MeOH (90 
L) at room temperature (Figure 4). After evaporation, the MeOH extract (after dilution with 
H2O) was subjected to solvent-solvent partitioning to obtain CHCl3- and H2O-soluble 
fractions. The alkylamide-containing CHCl3 phase was concentrated in vacuo, yielding 80 g 
of material, which was subjected to silica gel VLC (2 × 250 g), with a gradient system of n-
hexane–EtOAc (10:0, 9:1, 8:2, 7:3, 1:1, 0:10). In total, 78 fractions were collected, and 
combined into 12 main fractions (I–XII) on the basis of TLC monitoring.  
Alkylamide- and lignan-containing fractions (VIII–IX, 9 g) were selected for further 
purification, which was carried out by RP-VLC, using MeOH–H2O (8:2, 85:15, 9:1, 10:0) and 
then MeOH–EtOAc (9:1, 6:4, 10:0) gradient systems. From the total of 75 fractions, selected 
ones (fractions 17–22, 470 mg; 23-34, 2.4 g; 35–40, 1.15 g; and 41–46, 668 mg) were further 
processed. 
Fraction 17–22 was chromatographed on a 1-mm silica gel RPC plate with a gradient 
system of n-hexane–EtOAc (9:1, 8:2, 7:3, 0:1) at a flow rate of 3 mL/min (RPC I). Finally, 
the fractions obtained were purified by preparative TLC (benzene–CH2Cl2–Et2O, 1:1:1), 
which resulted in pure compound 6 (4 mg). 
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Fractions 23–34, 35–40 and 41–46 were purified by MPLC with a gradient system of n-
hexane–EtOAc (1:0, 9:1, 8:2, 7:3, 6:4, 1:1, 0:1) at a flow rate of 60 mL/min (MPLC I).  
Through the above-mentioned MPLC purification fraction 23–34 was separated into 5 
main subfractions, 1 of which contained the pure compound 3 (5 mg). Subfraction 1 was 
further chromatographed with MPLC I, yielding 60 fractions, among which fraction 25–42 
was subjected to RPC (4-mm RPC plate, 8 mL/min flow rate, gradient system of n-hexane–
EtOAc (9:1, 8:2, 7:3, 0:1) (RPC II), which resulted in the isolation of compound 5 (6 mg). 
Fraction 35–40 was separated into 45 subfractions, among which 25–29 was subjected 
to multiple RPC (2-mm silica gel RPC plate, gradient system of benzene–CH2Cl2–Et2O 9:3:0, 
6:3:0, 6:3:0,5; 5 mL/min flow rate) (RPC III). Final purification was carried out by 
preparative TLC (benzene–CH2Cl2–Et2O 6:3:1) (PLC II), which yielded compounds 4 (13 
mg) and 5 (8 mg). Subfraction 30–40 was chromatographed on a 2-mm silica gel RPC plate 
(n-hexane–Me2CO 9:1, 8:2, 7:3, 0:1; 5 mL/min flow rate), and then purified twice on a 1-mm 
RPC plate at a 3 mL/min flow rate (RPC IV), affording compound 4 (15 mg). Fraction 41–45 
was purified by RPC (1 mm plate, benzene–CH2Cl2–Et2O, 1:1:1; 3 mL/min flow rate) (RPC 
V), and then by PLC, using 2 solvent systems: PLC I and then n-hexane–Me2CO, 8:2 (PLC 
III), resulting in compound 6 (3 mg). 
Fraction 41–46 was separated into 78 fractions, of which fractions 7–19 and 20–36 
were selected for further separations. Fraction 7–19 was subjected to PLC (n-hexane–Et2O, 
6:4, PLC IV), and the almost pure fractions were then injected for RP-HPLC (MeCN–H2O, 
8:2), which resulted in the isolation of compounds 1 (6 mg) and 2 (2 mg). Fraction 20–36 was 
further chromatographed by RPC with a gradient system of n-hexane–Me2CO (9:1, 8:2, 1:0). 
The material was subjected to a 1-mm silica gel RPC plate, at a flow rate of 3 mL/min (RPC 
VI). Three main fractions were collected (1–3), two of which (1 and 3) were further purified 
by PLC I, affording the pure compounds 5 (4 mg) and 7 (3 mg). The third fraction was finally 
purified by HPLC (n-hexane–EtOAc, 8:2), resulting in compound 3 (2 mg). 
Fraction 47–55 was subjected to RPC with a gradient system of n-hexane–EtOAc (9:1, 
8:2, 0:1). The material was chromatographed on a 1-mm silica gel RPC plate at a 3 mL/min 
flow rate (RPC VII). Some of the yielded fractions were subjected to HPLC (n-hexane–
EtOAc, 8:2), affording compound 1 (5 mg). 
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Figure 4. Isolation of compounds from H. helianthoides var. scabra 
 
5.4. STRUCTURE ELUCIDATION  
The structures of the isolated compounds were determined by means of spectroscopic 
methods and by comparison of the spectral data with literature data. HRMS measurements 
allowed the determination of the exact molecular weights and molecular compositions of the 
compounds. Fragmentation of the molecules was studied by APCIMS.  The most informative 
methods in the structure elucidation were 1D and 2D NMR methods, including 
1
H NMR, 
JMOD, 
1
H-
1
H-COSY, NOESY, HMQC and HMBC techniques.  
5.4.1. Alkamides from Lepidium meyenii 
Three macamides were identified as N-(3-methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide 
(1), N-benzyl-(9Z,12Z,15Z)-octadecatrienamide (2) and N-benzyl-(9Z,12Z)-
octadecadienamide (3) by comparison of their 
1
H NMR spectral data with those reported in 
the literature.
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5.4.2. Alkamides from Heliopsis helianthoides var. scabra  
Compound 4 was isolated as a colorless oil with a strong tingling effect characteristic of 
numerous NAAs.
35
 It was shown by APCIMS to have a quasimolecular ion peak at m/z 326 
[M+H]
+
, which resulted in a fragment ion at m/z 253 in the MS
2 
due to the loss of 
isobutylamine. In accordance with this, the 
1
H NMR spectrum of 4 confirmed an N-
isobutylamide part of the molecule [δH 3.15 t, 1.80 sept, 0.91 d (6H)], and additionally 
contained signals proving the octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid 
isobutylamide structure.
44
 This compound was isolated earlier from another species of the 
genus (H. buphthalmoides),
44,51
 but 
its 
13
C NMR data are reported here 
for the first time. 
(4): 
1
H NMR (CDCl3, 500 MHz)  5.85 (1H, d, J = 15.0 Hz, H-2), 7.18 (1H, dd, J = 15.0, 10.8 Hz, H-3), 6.15 
(1H, dd, J = 15.1, 10.8 Hz, H.4), 6.07 (1H, m, H-5), 2.29 (4H, m, H-6, H-7), 5.93 (1H, dt, J = 10.8, 3.2 Hz, H-8), 
6.63 (1H, dd, J = 15.1, 10.8, H-9), 6.33 (1H, t, J = 10.8, H-10), 5.50 (1H, dd, J = 10.6, 1.6, H-11), 5.66 (1H, d, J 
= 10.5, H-14), 6.08 (1H, m, H-15), 2.33 (2H, q, J = 7.4 Hz, H-16), 1.47 (2H, m, H-17), 0.95 (3H, t, J = 6.5 Hz, 
H-18), 3.15 (1H, t, J = 6.5, H-2'), 1.80 (1H, sept., J = 6.7 Hz, H-3'), 0.91 (6H, d, J = 6.7 Hz, H-4', H-5'); 
13
C-
NMR (CDCl3, 125 MHz)  166.4 (C-1), 143.5, 141.1, 140.6, 139.0, 136.7, 128.8, 128.4, 122.4, 109.3, 107.7 (C-
2 – C-5, C-8 – C-11, C-14, C-15), 92.4, 90.8 (C-12, C-13), 46.9 (C-1'), 32.4, 32.3, 32.2, 32.1 (C-6, C-7, C-16, C-
17), 28.5 (C-1'), 22.0 (C-2'), 20.0 (C-3', C-4'), 13.8 (C-18); APCIMS (positive) m/z 326 [M+H]
+
, 253 
[(M+H)C4H11N]
+
, 225 [(M+H)C4H11NCO]
+
, 211 [(M+H)C4H11NCH2CO]
+
, 185, 181, 171, 158, 143, 131, 
117. 
Compound 5 was obtained as a colorless oil with a light tingling effect. Its APCIMS 
spectrum contained a quasimolecular peak at m/z 340 [M+H]
+
, which afforded the fragment 
ions m/z 253 [(M+H)C5H13N]
+
, 235 [(M+H)C5H13NH2O]
+
, 225 [(M+H)C5H13NCO]
+
, 
211 [(M+H)C5H13NCH2CO]
+
, revealing a methylbutylamide structural part. Analysis of the 
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1
H NMR spectrum confirmed that compounds 4 and 5 are homologues since they exhibited 
the same spectroscopic features as regards the acid part of the molecule. The 
1
H NMR spectra 
were different only in the signals of a 2-methylbutylamide [H 3.28 m (H-2'a), 3.15 m (H-2'b), 
1.57 m (H-3'), 1.40 m (H-4'a), 
1.17 m (H-4'b) and 0.91 (H-5', 
H-6')] in compound 5 instead 
of isobutylamide. The new compound 5 was therefore assigned as octadeca-
2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid 2'-methylbutylamide. 
(5): 
1
H NMR (CDCl3, 500 MHz)  5.78 (1H, d, J = 15.0 Hz, H-2), 7.19 (1H, dd, J = 15.0, 10.9 Hz, H-3), 6.15 
(1H, dd, J = 15.0, 10.4 Hz, H.4), 6.06 (1H, m, H-5), 2.27 (4H, m, H-6, H-7), 5.93 (1H, m, H-8), 6.64 (1H, dd, J = 
15.0, 10.9, H-9), 6.33 (1H, t, J = 10.9, H-10), 5.51 (1H, brd, J = 10.4, H-11), 5.66 (1H, d, J = 10.4, H-14), 6.06 
(1H, m, H-15), 2.33 (2H, q, J = 7.3 Hz, H-16), 1.47 (2H, m, H-17), 0.96 (3H, t, J = 7.4 Hz, H-18), 3.28 (1H, m, 
H-2'a), 3.15 (1H, m, H-2'b), 1.57 (1H, m, H-3'), 1.40 (1H, m, H-4'a), 1.17 (1H, m, H-4'b), 0.91 (3H, t, J = 7.2 Hz, 
H-5'), 0.91 (3H, d, J = 6.8 Hz, H-6'); APCIMS (positive) m/z 340 [M+H]
+
, 253 [(M+H)C5H13N]
+
, 235 
[(M+H)C5H13NH2O]
+
,
 
225 [(M+H)C5H13NCO]
+
, 211 [(M+H)C5H13NCH2CO]
+
, 185, 181, 159; 
HRESIMS m/z 340.2559 [M+H]
+
 (calcd for C23H34NO, 340.2562). 
Compound 6 was isolated as colorless oil, and its HRESIMS displayed a quasimolecular ion 
peak at m/z 298.2094 [M+H]
+
, indicating the molecular formula C20H27NO. The 
1
H and 
13
C 
NMR spectra exhibited resonances for an isobutylamide [H 3.17 t (H-2'), 1.81 sept. (H-3'), 
0.93 d (H-4', 5'); C 46.9 (C-2'), 28.6 (C-3') and 20.1 (C-4',5')] and a polyunsaturated C16 acid 
part. From the HSQC spectrum, the chemical shifts of the protonated carbons were assigned, 
and the proton-proton connectivities 
were then studied. The 
1
H-
1
H COSY 
spectrum defined the following 
structural fragment with correlated protons: -CH=CH-CH=CH-CH2-CH2-CH2-CH=CH-CH2- 
[H 5.78 d, 7.19 dd, 6.15 dd, 6.03 dt, 2.16, 1.52 dq, 2.04 q, 5.48 dt, 5.40 dt and 3.01 d (H-2 – 
H-11)]. This structural unit, a tertiary methyl (H 1.95 s), the carbonyl carbon (C 166.3) and 
acetylene carbons (C 75.2, 64.9, 60.9 and 59.7), were connected by analysis of the long-range 
C–H correlations observed in the HMBC spectrum. The two- and three-bond correlations 
between the carbonyl carbon (C 166.3), and the proton signals at H 5.78 and 7.19 (H-2 and 
H-3), between the methyl group (H 1.95 s) and C 64.9 and 60.9 (C-14 and C-15) 
demonstrated the presence of a hexadeca-2,4,9-trien-12,14-diynoic acid isobutylamide 
structure. The geometry of the C-2/C-3 and C-4/C-5 double bonds was concluded to be E 
from the coupling constants (J = 15.5 and 15.1 Hz, respectively), and Z for the C-9/C-10 
olefinic unit with regard to the J = 10.3 Hz coupling constant. Based on these data, the 
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structure hexadeca-2E,4E,9Z-trien-12,14-diynoic acid isobutylamide (6) was elucidated for 
this compound. 
(6): 
1
H NMR (CDCl3, 500 MHz)  5.78 (1H, d, J = 15.5 Hz, H-2), 7.19 (1H, dd, J = 15.5, 10.8 Hz, H-3), 6.15 
(1H, dd, J = 15.1, 10.8 Hz, H-4), 6.03 (1H, dt, J = 15.1, 7.0, H-5), 2.16 (2H, J = 7.0 Hz, H-6), 1.52 (2H, dq, J = 
7.3, 7.3 Hz, H-7), 2.04 (2H, q, J = 7.1 Hz, H-8), 5.48 (1H, dt, J = 10.3, 7.2 Hz, H-9), 5.40 (1H, dt, J =10.3, 6.8 
Hz, H-10), 3.01 (2H, d, J = 7.3 Hz, H-11), 1.95 (3H, s, H-16), 5.53 (1H, brs, NH), 3.17 (2H, t, J = 6.5 Hz, H-2'), 
1.81 (1H, sept, J = 6.7 Hz, H-3'), 0.93 (6H, d, J = 6.7 Hz, H-4', 5'); 
13
C-NMR (CDCl3, 125 MHz )  166.3 (C-1), 
122.1 (C-2), 141.0 (C-3), 128.9 (C-4), 142.1 (C-5), 32.1 (C-6), 28.0 (C-7), 26.4 (C-8), 132.3 (C-9), 122.4 (C-10), 
17.8 (C-11), 75.2, 64.9, 60.9, 59.7 (C-12 – C-15), 4.5 (C-16), 46.9 (C-2'), 28.6 (C-3'), 20.1 (C-4', C-5'); 
HRESIMS m/z 298.2094 [M+H]
+
 (calcd for C20H28NO, 298.2092). 
Compound 7, a colorless oil with a strong tingling effect, was found to have the molecular 
formula C21H35NO as confirmed by the 
quasimolecular ion peak at m/z 317.2717 
in the HRESIMS. In accordance with this, 
the 
1
H and 
13
C NMR spectra showed signals for a 2-methylbutylamide [H 3.28 m (H-2’a), 
3.15 m (H-2’b), 1.57 m (H-3’), 1.40 m (H-4’a), 1.17 m (H-4’b) and 0.93 t (H-5’, H-6’); C 
45.2 (C-2’), 35.0 (C-3’), 27.0 (C-4’), 11.3 (C-5’) and 17.2 (C-6’)]. Additionally, the NMR 
spectra exhibited resonances for a C16 unsaturated fatty acid residue containing 1 methyl, 6 
methylene, 8 methine and 1 carbonyl group. Analysis of the proton-proton connectivities in 
the 
1
H-
1
H COSY spectrum led to the identification of the hexadeca-2,4,9,12-tetraenoate 
chain. The stereochemistry of the C-2/C-3 and C-4/C-5 olefins was established as E on the 
basis of the coupling constants J2,3 15.0 and J4,5 15.3 Hz. Unfortunately, the E or Z geometry 
of the C-9/C-10 and C-12/C-13 double bond could not be determined because of the 
overlapping proton signals. The HMBC spectrum provided information on the connection of 
the acyl and amine parts of the molecule by long-range correlation between C-1 (C 166.1) 
and H-2’ (H 3.28 m and 3.15 m), and corroborated the hexadeca-2,4,9,12-tetraenoate 
structure. The above evidence confirmed the structure of compound 7 as hexadeca-
2E,4E,9,12-tetraenoic acid 2’-methylbutylamide.  
(7): 
1
H NMR (CDCl3, 500 MHz)  5.75 (1H, d, J = 15.0 Hz, H-2), 7.19 (1H, dd, J = 15.0, 10.6 Hz, H-3), 6.14 
(1H, dd, J = 15.3, 10.6 Hz, H-4), 6.05 (1H, dt, J = 15.3, 6.8, H-5), 2.17 (2H, J = 6.8 Hz, H-6), 1.50 (2H, m, H-7), 
2.06 (2H, m, H-8), 5.46 (4H, m, H-9, H-10, H-12, H-13), 3.02 (1H, brd, J = 5.1 Hz, H-11a), 3.09 (1H, d, J = 5.7 
Hz, H-11b), 2.06 (2H, m, H-14), 1.41 (2H, m, H-15),  0.92 (3H, t,  J = 7.0 Hz, H-16), 3.28 (1H, m, H-2'a), 3.15 
(1H, m, H-2'b), 1.57 (1H, m, H-3'), 1.41 (1H, m, H-4'a), 1.17 (1H, m, H-4'b), 0.93 (3H, t, J = 7.2 Hz, H-5'), 0.93 
(3H, d, J = 6.8 Hz, H-6'); 
13
C NMR (CDCl3, 125 MHz)  166.1 (C-1), 122.0 (C-2), 141.0 (C-3), 128.6 (C-4), 
142.4 (C-5), 32.3 (C-6), 28.4 (C-7), 26.5 (C-8), 2 × 124.9 and 2 × 130.9 (C-9, C-10, C-12, C-13), 17.8 (C-11), 
26.5 (C-14), 22.5 (C-15), 13.6 (C-16), 45.2 (C-2'), 35.0 (C-3'), 27.0 (C-4'), 11.3 (C-5’), 17.2 (C-6'); HRESIMS 
m/z 318.2717 [M+H]
+
 (calcd for C21H36NO, 318.2718). 
5.4.3. Lignans from Heliopsis helianthoides var. scabra 
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Compound 8 was isolated as an amorphous solid. HRESIMS and detailed 1D and 2D NMR 
spectroscopic studies indicated the 2-arylbenzofuran-type norneolignan structure. The 
positive-ion HRESIMS spectrum revealed the quasimolecular ion peak at m/z 361.1045 
[M+Na]
+
 (calcd for 361.1052 C20H18O5Na), indicative of the molecular formula C20H18O5. 
From the 
1
H NMR and JMOD spectra, 2 methoxy (H 4.05 s, 3.41 s, C 56.1, 56.9) and 1 
methylenedioxy groups (H 6.01 s, C 101.3) were clearly identified, in addition to a 17 
carbon-containing skeleton involving 8 quaternary carbons, 8 methine groups and 1 
methylene groups. The 
1
H-
1
H COSY spectrum revealed 2 aromatic rings, 1 tetrasubstituted 
ring (ring A) according to the correlation of the protons at H 7.14 (H-4) and 6.87 (H-6), and 1 
trisubstituted ring (ring B), as demonstrated by the correlative signals of an ABX spin system 
[H 7.32 d (0.7) (H-2'), 6.87 d (8.1) (H-5') and 7.40 brd (8.1) (H-6')]. Further, the 
1
H-
1
H 
COSY spectrum showed the presence of an unsaturated C3 unit with correlated protons at H 
6.67, 6.26 and 4.12 ppm. These structural parts, 
together with a quaternary carbon (C 156.3) and an 
isolated methine (H 6.82 s, C 100.5), were 
connected by inspection of the long-range C–H 
correlations observed in the HMBC spectrum. The 2- and 3-bond correlations between the 
quaternary carbon C-2 and H-3 and H-2', and between the methine proton H-3 and C-9 and C-
8 signals revealed that rings A and B are connected through a furan ring, altogether forming a 
norneolignan structure. The correlations of the methoxy signal at δH 4.05 with the carbon 
signal δC 145.2 (C-7) indicated the presence of the methoxy group on C-7. Similarly, the 
HMBC cross-peak of the methoxy signal at δH 3.41 with the carbon signals at δC 73.2 (C-3") 
demonstrated the connection of the methoxy group to the C3 unit. The position of this 3"-
methoxypropenyl group on C-5 was proved by the long-range correlation between C-1" and 
H-4 and H-6. The methylenedioxy group on ring B was indicated by the 3-bond HMBC 
correlations between the proton signal at H 6.01 and C-3' and C-4'. The substitution pattern 
was also corroborated by the NOESY cross-peaks between H-3/H-2', 7-OCH3/H-6, H-6/H-1", 
H-1"/H-4, H-4/H-3 and 3"-OCH3/H-3". The E geometry of the C-1"/C-2" olefin was deduced 
from the coupling constant of 15.8 Hz. All of the above evidence confirmed the structure of 
this compound as 1"-dehydroegonol 3"-methyl ether (8).  
 (8): 
1
H NMR (CDCl3, 500 MHz)  6.82 (1H, s, H-3), 7.14 (1H, brs, H-4), 6.87 (1H, brs, H-6), 7.32 (1H, d, J = 
0.7 Hz, H-2’), 6.87 (1H, d, J = 8.1 Hz, H-5’), 7.40 (1H, brd, J = 8.1 Hz, H-6’), 6.67 (1H, d, J = 15.8 Hz, H-1”), 
6.26 (1H, dt, J = 15.8, 6.1 Hz, H-2”), 4.12 (2H, d, J = 6.0 Hz, H-3”), 4.05 (3H, s, 7-OCH3), 3.41 (3H, s, 3”-
OCH3), 6.01 (2H, s, 3”-OCH2O-); 
13
C NMR (125 MHz, CDCl3)  156.7 (C-2), 100.5 (C-3), 111.8 (C-4), 137.8 
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(C-5), 104.7 (C-6), 144.8 (C-7), 142.8 (C-8), 131.0 (C-9), 124.8 (C-1’), 105.5 (C-2’), 148.2 (C-3’), 148.2 (C-4’), 
108.6 (C-5’), 119.3 (C-6’), 133.1 (C-1”), 124.8 (C-2”), 73.2 (C-3”), 56.1 (7-OCH3), 56.9 (3"-OCH3), 101.3 (-
OCH2O-). HRESIMS m/z 361.1045 [M+Na]
+
 (calcd for C20H18O5Na, 361.1052); APCIMS positive m/z 339 
[M+H]
+
, 307 [(M+H)CH3OH]
+
, 279 [(M+H)CH3OHCO]
+
, 249, 221, 149.
 
 
 
Compound 9 was obtained as an amorphous solid. Its HRESIMS spectrum displayed a 
quasimolecular ion peak at m/z 363.1202 [M+Na]
+
, indicating the molecular formula 
C20H20O5. Similarly as in the case of compound 8, the 
1
H NMR and JMOD spectra showed 
the presence of 2 methoxy (H 4.03 s, 3.36 s, C 56.1, 58.6) and 1 methylenedioxy (H 6.01 s, 
C 101.3) substituents in 9. After the 
1
H and 
13
C NMR data on 9 had been assigned by 
analysis of its 
1
H-
1
H COSY, HSQC and HMBC 
spectra, it was obvious that compounds 8 and 9 are 
based on the same parent system and differ only in the 
C3 side-chain. The absence of signals of a disubstituted 
olefin group (C-1", C-2") and the appearance of signals of a saturated C3 side-chain (H 2.75 t, 
1.94 dq, 3.41 t, C 32.6, 31.8, 71.9) indicated the presence of a 3"-methoxypropyl group in 9, 
in contrast with the 3"-methoxypropenyl residue in 8. All of the above data were compatible 
with the egonol 3"-methyl ether structure of compound 9.  
(9): 
1
H NMR (CDCl3, 500 MHz)  6.79 (1H, s, H-3), 6.96 (1H, s, H-4), 6.63 (1H, s, H-6), 7.32 (1H, s, H-2’), 
6.87 (1H, d, J = 8.1 Hz, H-5’), 7.40 (1H, d, J = 8.0 Hz, H-6’), 2.75 (2H, t, J = 7.7 Hz, H-1”), 1.94 (2H, dq, J = 
7.1, 6.5 Hz, H-2”), 3.41 (2H, t, J = 6.4 Hz, H-3”), 4.03 (3H, s, 7-OCH3), 3.36 (3H, s, 3"-OCH3), 6.01 (2H, s, -
OCH2O-); 
13
C NMR (125 MHz, CDCl3)  156.3 (C-2), 100.4 (C-3), 112.3 (C-4), 107.5 (C-6), 145.2 (C-7), 143.8 
(C-8), 131.1 (C-9), 124.8 (C-1’), 105.5 (C-2’), 148.1 (C-3’), 147.9 (C-4’), 108.6 (C-5’), 119.2 (C-6’), 32.6 (C-
1”), 31.8 (C-2”), 71.9 (C-3”), 56.1 (7-OCH3), 58.6 (3"-OCH3), 101.3 (-OCH2O-).  HRESIMS m/z 363.1202 
[M+Na]
+
 (calcd for C20H20O5Na, 363.1208); APCIMS positive m/z 341 [M+H]
+
, 309 [(M+H)CH3OH]
+
, 281 
[(M+H)CH3OHCO]
+
, 251, 223, 149. 
 
Compound 10 was obtained as a yellow substance with a strong blue 
fluorescence at 360 nm. It was identified as helioxanthin by 
comparison of its spectroscopic data with those published in the 
literature.
148
 Helioxanthin has been isolated from several genera, and it 
is the most widely investigated lignan from the Heliopsis genus.  
(10): 
1
H and 
13
C NMR data identical with those published in 
148
. APCIMS (positive 
mode) m/z 349 [M+H]
+
, 319 [(M+H)–CH2O]
+
, 305, 301, 291, 275. 
 
Compound 11, a colorless oil, was identified on the basis of ESIMS and 1D and 2D NMR 
spectroscopy as (7E)-7,8-dehydroheliobuphthalmin. This compound has earlier been 
reported from H. bupthalmoides, without 
13
C NMR spectroscopic data.
51
 In our 2D NMR 
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experiments, the chemical shifts assignment of all carbons were 
assigned as listed below. It has also been published from Biota 
orientalis leaves.
134 
 
(11): [α]24D = –175 (c 0.1, CHCl3); 
1
H NMR data: identical with published 
data;
51
 
13
C NMR (125 MHz, CDCl3)  149.5 (C-1, C-1'), 147.7 (C-2, C-2'), 
108.4 (C-3), 128.8 (C-4), 122.5 (C-5), 108.2 (C-6), 142.5 (C-7), 129.5 (C-8), 
167.1 (C-9), 109.4 (C-3'), 133.2 (C-4'), 122.1 (C-5'), 107.8 (C-6'), 35.7 (C-
7'), 45.5 (C-8'), 173.1 (C-9'), 101.2 (1,2- -OCH2O-), 100.7 (1',2'- -OCH2O-), 
52.0 (9-OCH3), 52.2 (9'-OCH3). 
     
 By means of APCIMS and 
1
H and 
13
C NMR spectroscopy and comparison of the measured 
data with published values,
133
 the amorphous solid compound 12 
was determined to be heliobuphthalmin with the threo 
configuration at C-8 and C-8'. This compound has also been 
identified from the whole plant of Justicia ciliata
149
 and the stem 
bark of Pycnanthus angolensis.
132
 
(12): [α]D
24
 = –3 (c 0.2, CHCl3); 
1
H and 
13
C NMR data: identical with those 
published in.
133
 APCIMS (positive mode) m/z 415 [M+H]
+
, 383 [(M+H)–
CH3OH]
+
, 351, 333, 135. 
From a consideration of its APCIMS spectrum and 
13
C NMR 
chemical shift values,
150 
compound 13 was found to be identical 
with 7-acetoxyhinokinin. Our 2D NMR analysis led to the 
complete assignment of the 
1
H NMR data as listed below.  
(13): [α]D
26
 = –46 (c 0.1, CHCl3); 
1
H NMR (CDCl3, 500 MHz)  6.65 (1H, s, H-
2), 6.36 (1H, d, J = 7.9 Hz, H-5), 6.64 (1H, d, J = 7.9 Hz, H-6), 6.14 (1H, d, J = 
3.4, H-7), 2.70 (1H, dd, J = 6.1, 3.4 Hz, H-8), 6.34 (1H, s, H-2'), 6.73 (1H, d, J = 7.9 Hz, H-5'), 6.65 (1H, d, J = 
7.9 Hz, H-6'), 2.46 (1H, dd, J = 13.8, 8.2 Hz, H-7'a), 2.35 (1H, dd, J = 13.8, 7.4 Hz, H-7'b), 2.81 (1H, m, H-8'), 
4.29 (1H, t, J = 8.7 Hz, H-9'a), 3.97 (1H, dd, J = 8.7, 5.6 Hz, H-9'b), 5.97, 5.96 (each 1H, s, -OCH2O-), 5.93, 
5.92 (each 1H, d, J = 1.0 Hz, -OCH2O-), 2.13 (3H, s, OAc); APCIMS (positive mode) m/z 413 [M+H]
+
, 353 
[(M+H)–CH3COOH]
+
. 
 
5.5. PHARMACOLOGICAL INVESTIGATIONS 
5.5.1. Pharmacological effects of N-Alkylamides 
The isolated NAAs were examined for their possible activities on different targets within the 
ECS by Jürg Gertsch et al (Institute of Biochemistry and Molecular Medicine, NCCR 
TransCure, University of Bern, Bern, Switzerland).
145
 
From the studied compounds (1, 3-7) no NAA had any significant effect on MAGL 
(which is the major 2-arachidonoylglycerol-degrading enzyme). Only macamide 3 showed a 
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low micromolar inhibition of FAAH (IC50 = 4.07 µM), as expected.
75
 Compound 3 caused a 
significant submicromolar inhibition of AEA uptake (IC50 = 0.67 µM), which was even more 
potent than the inhibition measured with the reference inhibitors OMDM-2 (IC50 = 4.12 µM ) 
and UCM707 (IC50 = 1.46 µM. Because the AEA cellular uptake inhibition by 3 was more 
potent than the FAAH inhibition, this compound shows certain selectivity toward the first 
process. Only 3 also showed a significant binding affinity toward CB receptors, with an 
unexpected tenfold selectivity towards CB1 (Ki = 0.48) over CB2 receptors (Ki = 4.11). The 
NAAs from H. helianthoides var. scabra were not active on FAAH or AEA uptake, but 7 
showed a potent binding interaction with the CB1 receptor (Ki = 0.31 µM). 
Table 2. Summary of the effects of the isolated NAAs on ECS targets.
a
 
Cpd.  
AEA cell 
uptake  
IC
50 
(μM)  
 
(95% CI) 
Effi- 
cacy 
(%)  
FAAH
 
IC
50 
(μM)  
 
(95% CI) 
Effi- 
cacy 
(%)  
MAGL
 
IC
50 
(μM)  
 
- 
CB
1
 
K
i
 (μM)  
 
(95% CI) 
CB
2
  
K
i 
(μM)  
 
(95% CI) 
1  >100  44  
19.05 
(13.8–28.18) 
85  >100  
8.67 
(4.66–13.75) 
>50  
2  
84.36 
(72.44–>100)  
53  
11.48 
(6.81–18.78) 
85  >100  
8.88 
(3.79–10.19) 
43.96 
(24.16–>50) 
3  
0.67 
(0.47–0.97)  
73  
4.07 
(2.95–5.62) 
83  >100  
0.48 
(0.33–0.67)  
4.11 
(3.11–5.66) 
4  
2.45 
(1.28–4.70)  
75  
17.78 
(13.18–25.70) 
84  > 100  
8.60 
(2.39–10.92) 
 9.18 
(5.41–9.84) 
6  
4.33 
(2.69–6.97)  
75  12.30  79  >100  
>20 
(6.28–>20) 
 22.55 
(12.68–25.30) 
7 
2.15 
(0.87–5.31)  
51  
19.95 
(12.59–33.11) 
80  >100  
0.31 
(0.18–0.59)  
1.21 
(0.90–1.71) 
OMDM-2 
4.12 
(2.01 – 12.19) 
72 
23.29 
(10.72 – 48.98) 
82 n.d. n.d. n.d. 
UCM707 
1.46 
(1.18 – 1.80) 
67 
7.24 
(6.03 – 13.18) 
79 n.d. n.d. n.d. 
a
 Data are mean values from at least three independent experiments, and the 95% confidence interval 
(CI) is shown; OMDM-2 and UCM-707 were used as positive controls for AEA uptake. n.d., not 
determined. 
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5.5.2. Pharmacological effects of lignans 
All of the isolated lignans (8-13) were examined for their possible activities on melanomas 
brain metastases formation by János Haskó et al. (Institute of Biophysics, Biological 
Research Centre, Hungarian Academy of Sciences, Szeged, Hungary). The results are 
discussed in detail in 
146
 and in the Ph.D. thesis of János Haskó (under preparation).  
Briefly, the tested lignans had no cytotoxic effect on the brain endothelial cells and 
A2058 melanoma cells in the range of concentrations used during the experiments (1-10 µM). 
Only 10 and 11 (each 5 µM) induced morphological changes and both lignans effectively 
reduced the rate of migration of melanoma cells. Compound 10 (2 µM) decreased the number 
of melanoma cells attached to the endothelial layer compared to the untreated control, 
however the other compounds had no observed effect on the melanoma cell – endothelial cell 
interactions. 
Since only 10 and 11 were effective in the above-mentioned experiments, subsequent 
experiments were performed with 10 (5 µM) and 11 (5 µM in rat, 2 and 5 µM in human brain 
endothelial cells). A significant improvement of the barrier function of cerebral endothelial 
cells was observed in the presence of both compounds.  
Treatment of endothelial cells with 10 or 11 resulted in a more pronounced 
immunostaining of ZO-1 (an important protein component of tight junctions) on the edge of 
endothelial cells. Each of these compounds led to a significant concentration-dependent 
reduction (2-10 µM) in endothelial cell migration.  
5.6. QUALITY CONTROL OF MACA-CONTAINING DIETARY SUPPLEMENTS 
5.6.1. Method validation 
A linear calibration plot (y = 1 871 710.20x + 3 015.43) was established with a correlation 
coefficient (R
2
) of 1.00, which allowed reliable quantification. The N-benzyl-(9Z,12Z)-
octadecadienamide (3) (a major alkamide of Maca) content of 6 preparations was below the 
limit of detection and above the limit of quantification in the case of 8 products. The intraday 
precision ranged between 0.80 and 1.11%. These results underline the good repeatability of 
our method. The recovery was 97% (RSD% 0.80) for the first concentration, and 99.6% 
(RSD% 2.90) and 98.8% (RSD%) for the second and third concentrations, respectively. These 
results are in accordance with recovery values of previously published methods
41,151
 and 
confirm the good accuracy of our method. The stability revealed resulted that the N-benzyl-
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(9Z,12Z)-octadecadienamide contents of n-hexane extracts stored for 3 and 4 days at room 
temperature were 96.53 and 103.40% of those of the original samples. These results indicated 
that the decomposition of this macamide is not significant and analysis can therefore be 
carried out reliably on fresh samples. 
5.6.2. Product analysis 
A total of 14 Maca containing mono- (5) and multicomponent (9) preparations (distributed by 
11 companies) were randomly selected and purchased. The presence of Maca was confirmed 
in 8 products (Table 3). The HPLC-UV chromatograms (210 nm) of the Maca-containing 
products were similar to that of Raw Organic Maca Powder (Figure 5).  
 
 
Figure 5. HPLC-UV chromatogram of a Maca extract (210 nm)  
 
The Maca powders contained 28.0-225.8 µg N-benzyl-(9Z,12Z)-octadecadienamide (3) /g. In 
6 preparations, the concentration of the marker macamide was below the detection limit and 1 
preparation was adulterated with a synthetic phosphodiesterase inhibitor. Thiosildenafil, a 
derivative of sildenafil, was detected by TLC and HPLC-DAD (retention time 7.2 min, 
maximal UV absorption at 282 nm) in this product. 
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Table 3. Analysis of 14 Maca-containing dietary supplements  
Product (origin) Pharmaceutical 
form  
Recommended  
daily dosage 
MACA-3 
(µg/g 
product) 
MACA-3 in the 
recommended daily 
dosage (µg) 
1. (Peru) 
Raw Organic Maca 
Powder (yellow) 
powder
1 
3-5 g 193.1 
  
579.3–955.5  
2. (Peru) 
Red Maca Powder 
powder
1
 no data  225.8 
  
 
3. (Peru) 
Black Maca Powder 
powder
1
 no data  63.0  
4. (Peru) 
Gelatinized Maca 
Powder 
powder
1
 no data  28.0  
5. (Peru) tablet
1
 1500 mg 45.2 67.8 
6. (EU) capsule
2 
1 capsule 30.9 15.45 
7. (UK) capsule
2
 1 capsule per day for 5 
days, then 2 days break 
2.6 1.3 
8. (China) tablet
2
 1-2 tablets per day, for 
4-6 weeks 
13.9 13.9–27.8 
9. (China) capsule
2
 maximum 1 capsule in 
every 3 days 
n.d. Presence of thiosildenafil 
10. (China) capsule
2
 1-2 capsules 30 min 
before sexual activity 
n.d.  
11. (EU) capsule
2
 2 capsules before 
sexual activity 
n.d.  
12. (China) capsule
2
 1-2 capsules 1 hour 
before sexual activity 
n.d.  
13. (China) ampole
2
 1 ampole n.d.  
14. (UK) spray
2
 3-5 puffs locally  n.d.  
1, 
monocomponent, 
2
 multicomponent preparations 
 
6. DISCUSSION 
6.1. TREATMENT OF CNS DISTURBANCES WITH PLANTS FROM THE 
MEDICINE OF PORVENIR 
The Bajo Paraguá CTO has one physician, who lives in the largest community, Piso Firme, 
and visits the other villages about once a month or in the event of emergency. There is a nurse 
too, who lives in Porvenir, but the inhabitants prefer their own, traditional medicine and 
contact the nurse merely secondarily, or the physician only in grave cases. There is one 
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traditional healer in the community, but he is known as a “black healer”, and is therefore not 
too popular. The majority of the inhabitants who are advanced in years tend to make use of 
self-therapy. The medicine in the community reflects the local traditions and their changes 
very well. The low number of rituals and plants used for them, and the ever more frequent 
communication with other communities or towns demonstrate how the community is coming 
under the influence of conventional medicine, and converting to a modern Bolivian rural 
community. 
In the most recent review article on this topic, more than 300 plant species are listed that are 
used for the treatment of CNS ailments by 26 native ethnic groups in Brazil.
152
 The study 
reviews 67 different diseases or effects possibly related to the CNS, where the main 
categories are analgesics, antifebriles, tonics and/or adaptogens, hallucinogens, anxiolytics, 
anticonvulsants, hypnotics, stimulants, weight control agents, memory enhancers, and others. 
The high proportion of plant species used as analgesics or to counteract fever is similar in 
Porvenir. The reason for the high number of antifebriles is the common occurrence of malaria 
accompanied by fever in Bajo Paraguá. Traditional ceremonies have barely been observed; 
the utilization of psychoactive plants is not characteristic for the community. Three of the four 
plants used for nervousness are not endemic in the region; the species, and probably their 
application too arrived in Porvenir from the medicinal knowledge of the urban areas of 
Bolivia. It is believed by Bolivian people that if someone starts to work hard after eating a lot, 
or goes out into a strong “bad wind”, or bathes in a cold stream with a heated body, his face or 
other parts of the body may become paralysed for a time or forever. This is the arrebato, the 
symptoms of which suggest that it may be a stroke. Less aggressive forms of the symptoms 
are vertigo, nausea and pain in the bones. Utilization of weight-controlling species occurs in 
Porvenir, but in comparison with some Amazonian native traditions, where a slim appearance 
is not preferable and weight-gaining plants are used, one species used in Porvenir is indicated 
for gaining weight, and another is for losing weight, as in modern societies. The bath prepared 
with one species, Cedrela fissilis, is applied to “keep ghosts away”. It seems to be only a 
belief, but taking into consideration that this species contains a sedative volatile oil,
153
 the 
calming effect during the bath may also serve as a background for its application.  
The ethnobotanical data that do exist in the literature correspond closely with the 
utilization of the plants in Porvenir, but the great majority of the species used have not been 
widely investigated from phytochemical or pharmacological points of view. For example, 
Maclura tinctoria (Moraceae), mora, is a tree from the rainforest, the bark of which contains a 
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resin that was used to treat tooth pain by 5 interviewees in Porvenir, and is also utilized in 
numerous other communities for similar purposes. It is used by people in other communities 
of Bajo Paraguá,9 by the Ese’eja Indians from Bolivia,154 in Peru155 and by people in the 
Brazilian Mato Grosso.
156
 Peruvian people treat a sore throat with the plant, and use it as a 
purgative, diuretic and antiviral remedy, and, similarly as in the Mato Grosso, mora is applied 
to combat rheumatism.
156
 
6.2. ISOLATION OF COMPOUNDS 
The dried hypocotyl powder of L. meyenii was extracted with n-hexane, which was the most 
adequate among the different solvents tested for the extraction of NAAs. Further purification 
was carried out with centrifugal partition chromatography (CPC) combined with HPLC. CPC 
was used by us for the first time to isolate NAAs and, since it has no solid stationary phase, it 
proved to be very useful in the isolation of highly unstable compounds such as alkamides. 
From Maca, three compounds (1-3) were isolated in 5.0–92.0 mg (0.00041–0.0076% of the 
dry plant material). 
The phytochemical work on H. helianthoides var. scabra started with the TLC analysis of 
different cultivars of the species and their comparison with the TLC profiles of several NAA-
containing plants and NAAs isolated previously in our laboratory. In view of the similar TLC 
profile and the tingling effect typical for NAAs
35
 presented by the fresh root, the cultivar 
‘Asahi’ was selected for further work. The plant material was extracted with MeOH at room 
temperature by percolation. MeOH, an amphipolar solvent, was suitable for the extraction of 
both lipophilic and polar compounds. Solvent–solvent extraction with CHCl3 was applied in 
order to separate the apolar constituents. The purification was continued with more selective 
methods (VLC, RP-VLC, MPLC, RPC, PLC and HPLC). VLC and MPLC separation of the 
NAA- and lignan-containing fractions afforded crude fractionation of the main components. 
For final purification, RPC, PLC and HPLC were applied since these were the most effective 
and most selective methods. The preparative work was carried out with analytical TLC on 
silica gel with various solvent systems. TLC analysis was used to model the separation 
methods, to combine fractions, and to check the purity of the isolated compounds. The 
detection was carried out in UV light at 254 and 360 nm, followed by spraying with cc. 
H2SO4. Because of the instability of the double or triple bond-containing NAAs, fractions 
were stored under nitrogen at -10 °C during the isolation process. Ten compounds (4-13) were 
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isolated from H. helianthoides var. scabra yielding 2.0-15.0 mg (0.000022-0.00016% of the 
fresh plant material). 
6.3. STRUCTURE ELUCIDATION OF THE ISOLATED COMPOUNDS 
The structure determination of compounds 1-3 isolated from L. meyenii led to the 
identification of previously described
41
 polyunsaturated aromatic diene and triene amide 
macamides, which contain 18 carbon atoms in their aliphatic chain: N-(3-methoxybenzyl)-
(9Z,12Z,15Z)-octadecatrienamide (1), N-benzyl-(9Z,12Z,15Z)-octadecatrienamide (2) and N-
benzyl-(9Z,12Z)-octadecadienamide (3).  
From Heliopsis helianthoides var. scabra, three new (5, 6, 7) and one known (4) aliphatic 
isobutyl- and methylbutylamides with 16 and 18 carbon atoms and three to six double and 
triple bonds on their fatty acid chain were identified.  
Alkylamides are characteristic compounds for the Heliopsis genus. Octadeca-
2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid isobutylamide (4) was isolated previously from H. 
helianthoides,
44
 but its 
13
C NMR data are reported by us for the first time. Including the latter 
compound four isobutylamides were described from H. buphthalmoides.
44
 Two more 
isobutylamides, scabrin and heliopsin were identified previously from H. scabra.
45,46
 
Compared with the five known alkamides of H. longipes (A. Gray) Blake
42,43
 bearing 1-3 
double bonds, H. buphthalmoides (Jacq.) Dunal and H. helianthoides (L.) Sweet contain C18 
NAAs with the rarely occurring pentaene and hexaene acids. In the cases of the three new 
natural products octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid 2'-methylbutylamide (5), 
hexadeca-2E,4E,9Z-triene-12,14-diynoic acid isobutylamide (6), and hexadeca-2E,4E,9,12-
tetraenoic acid 2'-methylbutylamide (7), two of them contain acetylene bonds as well. 
Moreover, six lignans were determined from H. helianthoides var. scabra: two new 
arylbenzofuran neolignans, 1"-dehydroegonol 3"-methyl ether (8) and egonol 3"-methyl ether 
(9), and four known lignan derivatives (10-13). From three species of the Heliopsis genus, a 
wide variety of lignans have been identified previously. Helioxanthin (10), an arylnaphthalene 
derivative, was identified earlier from the root of this species
52
 and from thirteen other 
plants.
89,148,157–167
 The dibenzylbutyrolactone helianthoidin was isolated previously
53
 from the 
root of H. helianthoides var. scabra, but was not found by us. The dibenzylbutane (7E)-7,8-
dehydroheliobuphthalmin (11) and heliobuphthalmin (12) were isolated for the first time from 
H. helianthoides var. scabra, but earlier from H. buphthalmoides.
50
  Three more 
dibenzylbutane derivatives and the dibenzylbutyrolactone 7-acetoxyhinokinin (13) were 
41 
 
identified for the first time from H. helianthoides var. scabra, but earlier from Ruta pinnata 
L.
168
  
6.4. ACTIVITIES OF N-ALKYLAMIDES ON THE ENDOCANNABINOID SYSTEM 
Previous studies with NAAs have enabled the generation of some SAR information with 
respect to CB receptor binding.
169,170
 However, the binding interactions of NAAs with the 
CB1 or CB2 receptors do not reflect a straightforward SAR, because head group modifications 
and variations in alkyl chain length, and double bond configurations all appear to play a 
role.
67,73,169
 The potent new CB1 receptor ligand 7 comprises a methylbutylamide head group 
combined with the typical 2E,4E double bonds in the alkyl chain,
169
 with additional double 
bonds at carbons 9 and 12. This NAA shows an approximately four-fold selectivity for CB1 
receptors over CB2 receptors. Moderate CB1 receptor interactions have been described for 
NAAs, all containing the 2E double bond,
67,73
 but there is no clear SAR. Based on the 
findings with the macamides, it is possible to identify further crucial molecular elements for 
CB1 binding, FAAH and AEA transport inhibition. Macamide 3 seems to fulfil the criteria for 
endocannabinoid substrate mimicking, as this is the only NAA known so far to interact with 
several ECS targets at low micromolar or even submicromolar concentrations. It is tempting 
to speculate that the 9Z,12Z-octadecadiene alkyl chain present in 3 mimics the end of the 
arachidonoyl chain present in endocannabinoids. Thus, it will be interesting to develop this 
new insight further by studying NAAs with ideal head groups containing the 9Z,12Z-
octadecadiene alkyl chain. In the case of the macamide 3, the additional 15Z double bond 
present in compounds 1 and 2 is detrimental to potency. Interestingly, the N-benzylamide 
head group present in 3 seems to be ideal as substituted N-phenylamides have weaker 
potency.
171
 With respect to the combined significant direct and indirect ECS effects of 
macamide 3, future studies will have to establish whether this natural product is a functional 
agonist or antagonist at CB receptors. Moreover, it should be interesting to test whether the 
cannabimimetic action expected from this compound could relate to the 
ethnopharmacological use of Maca. Given the fact that CB1 receptors are expressed in sperm 
and that the ECS appears to play a role in fertility and sperm quality,
172
 the fertility enhancing 
effects of Maca that is widely reported in the ethnopharmacological literature
24,27,28 
should be 
studied in the light of the present data. It has already been shown that Maca supplementation 
improves rat
101–105
 and bovine
113
 sperm quality and it would be interesting to test the 
hypothesis that these effects are mediated, at least in part, by ECS-targeting macamides such 
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as compound 3. Overall, these results provide additional evidence of the structural and 
functional similarity between NAAs and endocannabinoids, potentially interlinking NAA 
chemodiversity, the use of NAA-containing medicinal plants and botanical dietary 
supplements with the ECS as a potentially major site of action. 
6.5. ACTIVITIES OF LIGNANS ON MELANOMAS BRAIN METASTASIS 
FORMATION 
Among various tumors, melanoma has very high tendency (75% of patients) to form brain 
metastases.
173,174
 After intravasation and dissemination of cancer cells, the adhesion and the 
migration of tumor cells across the wall of the blood vessels formed by endothelial cells, are 
the key steps in the formation of brain metastases.
175
  The successful inhibition of these steps 
might prevent the formation of these tumors.  
The in vitro studies show that 10 and 11 exhibit various effects on melanoma cells and 
brain endothelial cells: impede the migration of them and 10 inhibits the adhesion of 
melanoma cells to the brain endothelial cells. These observations suggest that these lignans 
may have the potential to interfere the dissemination and the attachment of melanoma cells to 
the blood vessels and the angiogenesis of the metastatic tumors. The enhancement of the 
barrier function of the endothelial cells caused by 10 and 11 was presumably due to the 
strengthening of tight junctions, as the ZO-1 staining indicated.  
The improvement of the barrier function – which seems to be the first confirmation in the 
case of lignans – may contribute to hinder the transmigration of tumor cells across the blood 
vessels of the brain, however further investigations are needed to study this effect. These 
results also draw attention to the possibility that dietary consumed lignans may play a role in 
the inhibition of brain metastases. 
6.6. QUALITY CONTROL OF DIETARY SUPPLEMENTS 
The ways and goals of application of Maca are Europe is largely different from the traditional 
uses. The most preferred recommendations for the products are “potency enhancer”, “for 
men”, “for the reproductive system”, and “mental and physical capacity enhancer”. Among 
thirty other herbal (28), animal (2) or fungal (1) ingredients the most preferred ones are 
Serenoa repens (labeled in 7 products), Panax ginseng (5), Ginkgo biloba (4) Rhodiola rosea 
(3) and Urtica dioica (3).
142
 The majority of these are widely used either for symptoms of the 
genitourinary system or as physical or sexual performance enhancers. In cases of 
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monocomponent preparations, the recommended daily posologies of Maca (1500–5000 mg 
dry hypocotyl powder) overlap with the effective dosages used in human studies,
24,27,28
 but for 
multicomponent products they are much lower, between 80 and 125 mg for 4 products; 500 
and 750 mg in two cases; and not declared in one case. 4 products were claimed to contain 
“maca extract” (unspecified), and in one case dry hypocotyl powder, while in four cases no 
further information was given. Since Peruvian Maca consumer natives ingest 65–260 g dry 
hypocotyl per day,
135
 even the relatively higher dosages used in human studies are too low to 
make a comparison between the traditional and the European applications of the plant.  
The HPLC method that we developed allowed the reliable analysis of one of the major 
macamides of L. meyenii. The good separation of N-benzyl-(9Z,12Z)-octadecadienamide from 
other components of the extracts proved the robustness of the method. HPLC-DAD analysis 
revealed that significant peaks with higher retention times than that of this compound do not 
relate to the class of macamides. Marked differences in macamide content could be detected 
in the cases of the different color types. The presence of Maca was confirmed in only 8 
products, but five of them were the only Maca-containing preparations. Thus, according to 
our method two-thirds of the randomly selected multicomponent products were of inferior 
quality, without any presence of Maca. Moreover, one of them was adulterated with the 
synthetic phosphodiesterase inhibitor, thiosildenafil. 
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7. SUMMARY 
The availability of the traditional knowledge about plants may lead to the development of 
several drugs for modern medicine or dietary supplements. The aims of the present study 
were to describe the traditional medicine utilized in Porvenir, Bolivia, and to discuss the plant 
species traditionally applied for CNS disturbances. Further goals were the isolation and 
structure elucidation of alkamides and lignans from Lepidium meyenii (Maca) and Heliopsis 
helianthoides var. scabra, both plants used in ethnomedicine, and in the frame of cooperation 
to test them on different targets of the CNS. Quality control of Maca-containing dietary 
supplements was also an aim. 
Porvenir is an indigenous Bolivian community, which houses the Chiquitano mestizos 
and the Guarasug’we indigenous nation currently close to extinction. The medicine in 
Porvenir reflects the local traditional roots and their changes very well, revealing how the 
population is coming under the influence of conventional medicine. Altogether 107 known 
complaints or symptoms were described, 11 of them relating for CNS illnesses or symptoms, 
for which 37 plant species are used. 
Phytochemical analysis of L. meyenii led to the isolation and structure elucidation of 
previously described macamides, N-(3-methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide (1), 
N-benzyl-(9Z,12Z,15Z)-octadecatrienamide (2) and N-benzyl-(9Z,12Z)-octadecadienamide 
(3). Analysis of the fresh roots of H. helianthoides var. scabra (Dunal) Fernald led to the 
isolation and structure elucidation of four N-alkylamides, octadeca-2E,4E,8E,10Z,14Z-
pentaen-12-ynoic acid isobutylamide (4), octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid 
2'-methylbutylamide (5), hexadeca-2E,4E,9Z-triene-12,14-diynoic acid isobutylamide (6) and 
hexadeca-2E,4E,9,12-tetraenoic acid 2'-methylbutylamide (7). Compounds 5-7 are new 
natural products, while 4 was isolated for the first time from this species.  
The N-methylbutylamide 7 and the N-benzylamide 3 showed submicromolar and 
selective binding affinities to the CB1 receptor (Ki values = 0.31 and 0.48 µM, respectively). 
Compound 3 also exhibited weak FAAH inhibition (IC50 = 4 µM) and was a potent inhibitor 
of AEA cellular uptake (IC50 = 0.67 µM), this inhibition being stronger than that observed 
with the controls. The pronounced ECS polypharmacology of compound 3 highlights the 
potential involvement of the arachidonoyl-mimicking 9Z,12Z double bond system in the 
linoleoyl group for the overall cannabimimetic action of NAAs. This study provides 
additional strong evidence for the endocannabinoid substrate mimicking of plant-derived 
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NAAs and reveals both the direct and indirect cannabimimetic action of the Peruvian Maca 
root.  
Further phytochemical investigation of H. helianthoides var. scabra resulted in the 
isolation of six lignans: two new arylbenzofuran neolignans, 1"-dehydroegonol 3"-methyl 
ether (8) and egonol 3"-methyl ether (9), and four known lignan derivatives, helioxanthin 
(10), (7E)-7,8-dehydroheliobuphthalmin (11), heliobuphthalmin (12) and 7-acetoxyhinokinin 
(13). 
Helioxanthin (10) and (7E)-7,8-dehydroheliobuphthalmin (11) exhibited various effects 
on melanoma and brain endothelial cells, with the potential to interfere with different steps of 
metastasis formation. These findings indicate that these compounds impede the migration of 
melanoma cells, and 11 inhibits the adhesion of melanoma cells to the brain endothelial cells. 
Both compounds also enhanced the barrier function and decreased the migratory properties of 
cerebral endothelial cells. These effects might be instrumental in preventing the 
transendothelial migration of melanoma cells and the vascularization of tumors.  
A simple and reliable analytical protocol for the qualitative and quantitative analysis of 
the Maca content of dietary supplements was developed. In half of the 14 randomly selected 
Maca products, through the measurement of marker compounds, the Maca content could be 
determined by our method based on TLC and HPLC-DAD analysis. However, in 6 food 
supplements the concentration of the marker macamide was below the limit of detection and 
one of the products was adulterated with a synthetic phosphodiesterase inhibitor. The 
calculated Maca contents in the recommended daily doses of the majority of products were 
below the widely accepted posology of the plant. Our results draw attention to the need for 
proper quality control of Maca-containing dietary supplements. 
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Annex 1. Macamides isolated previously from Lepidium meyenii
38–41
 
 
N-benzylpentadecanamide 
 
N-benzylhexadecanamide 
 
N-(3-methoxybenzyl) hexadecanamide 
 
N-benzylheptadecanamide  
 
N-benzyloctadecanamide 
 
N-benzyl-13-oxo-9E,11E-octadecadienamide 
 
N-benzyl-5-oxo-6E,8E-octadecadienamide 
 
  
 
N-benzyl-9Z-octadecenamide 
 
N-(3-methoxybenzyl)-9Z-octadecenamide 
 
N-benzyl-15Z-tetracosenamide 
 
N-benzyl-9-oxo-12Z-octadecenamide 
 
N-benzyl-9-oxo-12Z,15Z-octadecadienamide 
 
N-benzyl-9Z,12Z-octadecadienamide 
 
N-(3-methoxybenzyl)-9Z,12Z-octadecadienamide 
 
  
 
N-benzyl-9Z,12Z,15Z-octadecatrienamide 
 
N-(3-methoxybenzyl)-9Z,12Z,15Z-octadecatrienamide 
 
N-benzyloctanamide 
 
N-benzyl-9,16-dioxo-10E,12E,14E-octadecatriene amide 
 
N-benzyl-9-oxo-16-hydroxy-10E,12E,14E-octadecatrienamide 
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spilanthol or affinin (deca-2E,6Z,8E-trienoic acid isobutylamide), (H. longipes) 
 
  
homospilanthol (deca-2E,6Z,8E-trienoic acid 2-methylbutylamide), (H. longipes) 
 
 
undeca-2E,4E-diene-8,10-diynoic acid isobutylamide (H. longipes) 
 
 
undeca-2E-ene-8,10-diynoic acid isobutylamide (H. longipes) 
 
  
deca-2E-enoic acid isobutylamide (H. longipes) 
 
 
octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid isobutylamide (H. buphthalmoides) 
 
 
octadeca-2E,4E,8E,10Z-tetraen-12-ynoic acid isobutylamide (H. buphthalmoides) 
 
 
tetradeca-2E,4E,10Z-trien-8-ynoic acid isobutylamide (H. buphthalmoides) 
 
  
 
 
 
octadeca-2E,4E,8E,10E,14Z-pentaen-12-ynoic acid isobutylamide (H. buphthalmoides, H. 
helianthoides)  
 
 
scabrin (octadeca-2,4,8,10,14-pentaenoic acid isobutylamide) (H. scabra) 
 
 
 
heliopsin (octadeca-2,4,8,10,12,16-hexaenoic acid isobutylamide or octadeca-2,4,8,12,14,16-
hexaenoic acid isobutylamide), (H. scabra)  
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  heliobuphthalmin       8-hydroxyheliobuphthalmin   7Z-7,8-dehydroheliobuphthalmin  
 
 
 
 2-[(2H-1,3-benzodioxol-5-yl)methyl]-3-[(3,4-dimethoxyphenyl)methyl] succinic acid 
dimethylester 
       
 heliobuphthalmin lactone   5,7'-dehydroheliobuphthalmin lactone    hinokinin 
 
       
 2′-hydroxyhinokinin              helianthoidin             helioxanthin  
 
  
Annex 4. Plants used in Porvenir for the treatment of central nervous system disturbances 
No./Family/Latin name/ 
Voucher number 
Local 
name 
FU
a
 VU
b
 Part used CNS indication Preparative 
method 
Route of 
administration 
In formulas with 
Chenopodiaceae         
(1) Chenopodium 
ambrosioides L. 148 
caré 13 10 Leaves Arrebato
c
 Squeeze Internal and 
embrocation 
The fat of Ateles paniscus 
or cooking oil 
Apocynaceae         
(2) Aspidosperma rigidum 
Rusby 
gabetillo 7 5 Stem bark Fever Decoction Bath  
Arecaceae         
(3) Euterpe precatoria Mart. 
83 
asaí 7 7 Root Headache, dorsalgia  Jam Internal Saccharum officinarum 
(4) Attalea maripa (Aublet) 
Mart. 176 
cusi 
macho, 
casi cusi 
1 1 Seed oil Headache Crude Massage  
(5) Attalea speciosa Mart. cusi, cusi 
hembra 
13 8 Seed oil Fever, headache, 
Arrebato
c
 
Crude Embrocation  
Asteraceae         
(6) Bidens cynapiifolia 
Kunth 4 
pega pega 
espinuda 
  Root Sadness Decoction Internal Imperata brasiliensis and 
Carica papaya 
Bignoniaceae         
(7) Tabebuia aurea (Silva 
Manso) Benth. & Hook. f. ex 
S. Moore 164 
alcornoque 13 13 Stem bark Fever, weakness, 
alcoholism 
Decoction Internal Tabebuia impetiginosa 
Burseraceae         
(8) Protium spruceanum 
(Benth.) Engl. 87 
quina 3 3 Stem bark Dengue-fever Decoction Internal Citrus limon 
    Resin Headache Crude Massage  
(9) Trattinnickia 135 isiga 6 2 Resin Arrebato
c
, headache Crude Massage of the temporal The bone of Chrysocyon 
brachyurus 
         
         
  
No./Family/Latin name/ 
Voucher number 
Local 
name 
FU
a
 VU
b
 Part used CNS indication Preparative 
method 
Route of 
administration 
In formulas with 
Caricaceae         
(10) Carica papaya L. papaya 13 11 Flower Headache, 
nervousness 
Infusion Internal Colonia 
    Root Sadness Infusion Internal Imperata brasiliensis and 
Bidens cynapiifolia 
Cucurbitaceae         
(11) Citrullus lanatus 
(Thunb.) Matsum. & Nakai  
sandía 5 2 Seed Arrebato
c
 Milling, 
decoction 
Massage  
Euphorbiaceae         
(12) Jatropha curcas L. 48 piñón 13 10 Resin Alcoholism Put in an 
alcoholic 
drink 
Internal It provokes vomiting 
    Seed Alcoholism Milling and 
added to 
the food 
Internal  
    Leaves To lose weight Infusion Washing  
(13) Ricinus comunis L. 53 macororó 8 8 Fruit, seed Dorsalgia Milling and 
decoction 
Internal (drinking) and 
massage 
 
    Leaves, 
seed oil 
Fever, headache Crude Massage and/or 
covering 
 
Fabaceae         
(14) Hymenaea courbaril L. 
31 
paquió 8 6 Stem bark To gain weight Syrup Internal  
(15) Senna occidentalis (L.) 
Link 38 
mamúri 2 11 4 Root, 
leaves 
Fever Infusion Bath  
(16) Senna alata (L.) Roxb. 
52 
mamúri 1 11 6 Root, 
leaves 
Arrebato
c
, fever Decoction Bath  
(17) Mucuna rostrata Benth 
174 
ojo de toro 1 1 Seed Fever Toasting 
and 
maceration 
Internal  
(18) Ormosia coarctata 
Jackson 1 
sirari 1 1 Endosper
m 
Tooth ache Milling Covering  
         
  
No./Family/Latin name/ 
Voucher number 
Local 
name 
FU
a
 VU
b
 Part used CNS indication Preparative 
method 
Route of 
administration 
In formulas with 
Lamiaceae         
(19) Ocimum americanum 
L. 121 
alba haca 8 3 Whole 
plant 
Arrebato
c
 Infusion Bath  
Malvaceae         
(20) Gossypium 
barbadense L. 40 
algodón 7 6 Leaves Cold exudation
c
 Infusion Internal  
Meliaceae         
(21) Cedrela fissilis Vell. 
102 
cedro 3 3 Leaves / 
stem bark 
Keeping ghosts 
away 
Decoction Bath  
(22) Swietenia macrophylla 
King 
mara 1 4 Fruit Tooth ache Squeeze for 
juice 
Gargle  
Moraceae         
(23) Maclura tinctoria (L.) D. 
Don ex Steud 116 
mora 5 1 Resin Tooth ache Crude Dropping Salt 
Piperaceae         
(24) Piper 105 matico 
chico 
7 2 Stem / 
flower 
Tooth ache Crude Chew  
Poaceae         
(25) Imperata brasiliensis 
Trin. 107 
paja sujo 4 3 Root Sadness Decoction Internal Carica papaya and Bidens 
cynapiifolia 
(26) Cymbopogon citratus 
(DC.) Stapf 156 
paja 
cedrón 
11 3 Leaves Nervousness Infusion Internal The hoof of Tapirus 
baiirdei / colonia 
Rubiaceae         
(27) Cephaelis 
ipecacucanha (Brot.) A. 
Rich. 
poalla 3 2 Root Tooth ache Crude Covering  
    Root Fever No data No data  
Rutaceae         
(28) Citrus limon (L.) Burm 
100 
limon 13 20 Pulp Tooth ache, 
weakness 
Squeeze for 
juice 
Internal, massage, 
compress 
Honey, salt 
    Pulp Tooth ache Squeeze for Gargle Salt 
  
No./Family/Latin name/ 
Voucher number 
Local 
name 
FU
a
 VU
b
 Part used CNS indication Preparative 
method 
Route of 
administration 
In formulas with 
juice 
    Stem with 
leaves 
Tooth ache Infusion Gargle and washing of 
the head 
 
    Pulp Headache, fever Squeeze for 
juice 
Compress, washing of 
the head 
 
    Pulp Arrebato
c
 Squeeze for 
juice 
Foot-bath  
    Pulp Dengue-fever Squeeze for 
juice 
Internal Protium spruceanum 
(29) Citrus sinensis (L.) 
Osbeck 152 
naranja 
dulce 
7 3 Seed oil Headache Crude Head massage Jatropha curcas and 
cinnamon 
(30) Citrus reticulata Blanco 
154 
mandarina 2 2 Leaves Nervousness Infusion Internal  
Sapindaceae         
(31) Scoparia dulcis L. 36 basuriña 13 5 Whole 
plant 
Tooth ache Infusion Inhalation Salt and ashes 
Smilacaceae         
(32) Nicotiana tabacum L. tabaco 13 8 Leaves Headache, Heating Covering  
Indeterminated species         
(33) pesoé 10 9 Seed oil Headache, tooth 
ache 
Crude Embrocation  
(34) colonia 8 3 Flower Nervousness, 
headache 
Infusion Internal Carica papaya 
(35) pateanta 4 2 Seed oil? Arrebato
c
, fever Crude Massage  
(36) luisiña 1 1 Whole 
plant 
Fever Infusion Internal  
(37) cuta 1 2 Young 
leaves 
Cold exudation  Bath  
         
a
 Frequency of use, 
b 
Variety of use, 
c
 Explanations of the local words and expresions are to be found in the text. 
  
Annex 5. Isolated compounds 
 
N-Alkylamides from Lepidium meyenii 
 
 
N-(3-methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide (1) 
 
 
N-benzyl-(9Z,12Z,15Z)-octadecatrienamide (2) 
 
 
N-benzyl-(9Z,12Z)-octadecadienamide (3) 
 
N-Alkylamides from Heliopsis helianthoides var. scabra 
 
 
octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid isobutylamide (4) 
 
 
octadeca-2E,4E,8E,10Z,14Z-pentaen-12-ynoic acid 2'-methylbutylamide (5) 
 
 
hexadeca-2E,4E,9Z-trien-12,14-diynoic acid isobutylamide (6) 
 
 
hexadeca-2E,4E,9,12-tetraenoic acid 2’-methylbutylamide (7) 
 
  
Lignans isolated from Heliopsis helianthoides var. scabra 
 
 
1"-dehydroegonol 3"-methyl ether (8)      egonol 3"-ethyl ether (9) 
 
 
 
helioxanthin (10)  (7E)-7,8-dehydroheliobuphthalmin (11)   heliobuphthalmin (12) 
 
 
 
 
 
 
 
 
 
 
7-acetoxyhinokinin (13) 
 
